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Background: Pharmaceutical non-adherence as a consequence of large pill burdens is a noted issue in 
the management of cardiovascular disease risk (CVD), particularly for populations with high CVD risk 
or with coexisting comorbidities. Non-adherence to pharmaceuticals means the intended health 
benefit of the pharmaceutical is not realised and the targeted risk factor remains inadequately 
controlled. Fixed-dose combinations (FDCs) pharmaceuticals that combine one or more active 
compounds into a single pill are one method of reducing pill burdens. A body of literature illustrates 
that CVD FDC pharmacotherapy improves adherence and risk factor control, resulting in a reduction 
of CVD events and health system savings. Given this background, this thesis aimed to determine if 
switching individuals from monotherapies (an anti-hypertensive: amlodipine; and a statin: 
atorvastatin, [A+A]) to an equivalent FDC (amlodipine with atorvastatin, [FDC AA]) would be a health 
generating and cost-effective intervention for the primary prevention of CVD in the New Zealand 
context.  
Methods: Key parameters were identified in literature searches and meta-analyses were performed 
to determine the clinical efficacy for the FDC AA. An existing CVD multi-state life-table Markov model 
created by the BODE3 Research Group using rich New Zealand longitudinal data was adapted to model 
the effect of switching from A+A to the FDC AA in a population of New Zealand men aged 60 to 64 in 
2011. The two disease life-tables (stroke and coronary heart disease) were age, sex, and ethnicity-
specific (Māori and non-Māori). The model population was separated into five-year strata of absolute 
CVD risk (0:5%, >5:10%, >10:15%, >15:20%, >20%). The intervention period was five years. Initial 
uptake was the same for both regimens, but adherence and clinical efficacy were greater for FDC AA 
than the A+A regimen (based on the literature). The medication adherent population received the risk 
reduction benefits and therefore had lower CVD incidence within each risk stratum. Health system 
costs and quality-adjusted life-years (QALYs) were accrued over a lifetime horizon and discounted at 
3% annually (with variation in sensitivity and scenario analyses).  
Results: This was the first study to consider the cost-effectiveness of a CVD FDC in New Zealand and 
the first internationally to assess a CVD FDC by strata of CVD risk. Overall and within each of the CVD 
risk stratum, the use of the FDC AA resulted in additional QALY gains and additional cost-offsets (net 
cost-savings) compared to the use of A+A (albeit not significantly for costs). The incremental cost-
effectiveness ratio (ICER) in favour of switching to the FDC AA from A+A across all CVD risk strata 
ranged from cost-saving to $3,570 per QALY gained (or 280 QALYs per million dollars spent for the 
latter) at the upper bound of the 95% uncertainty interval (95%UI). The absolute QALYs gained and the 
cost-offsets (savings) were greatest in the lowest CVD risk strata (0:5%) with regimen switching 
resulting in an additional 167 QALYs gained and NZ$ 3.41 million in cost-offsets (savings). The total 
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QALYs gained and cost-offsets (savings) from regimen switching, decreased as CVD risk increased. But 
the per capita results suggested that individuals with the highest CVD risk, benefited the most from 
switching to the FCD AA regimen.  
Conclusions: This work provides modelling-level evidence that replacing the use of two monotherapies 
with a fixed-dose combination (a statin and anti-hypertensive) appears to be a cost-saving to very cost-
effective intervention for the primary prevention of CVD in New Zealand. Further research in other 
age/sex groups and with other types of CVD FDCs is required to increase the generalisability of these 
results. The results of this thesis provide strong support for health authorities in high-income countries, 
such as New Zealand, to consider the inclusion of such FDCs in CVD prevention guidelines, placing a 
higher value on reducing pill burdens and improving adherence. If such FDCs are not available, then 
regulatory authorities could solicit the pharmaceutical industry to apply for such products to be 
registered in their jurisdictions.  
Keywords: cost-effectiveness, cost-utility, fixed-dose combinations, adherence, cardiovascular 
disease, pill burdens, New Zealand.   
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Chapter 1: Introduction 
1.1 Context  
Cardiovascular disease (CVD) is associated with a considerable disease burden that impacts the health 
of individuals at a substantial cost to both the health system and society generally.1, 2 Internationally, 
primary prevention interventions that aim to reduce CVD risk by targeting CVD risk factors either at a 
population level (ie, mass-media campaign for tobacco control) or individual-level (ie, green 
prescription and pharmaceuticals) are numerous. Pharmaceutical interventions to reduce the risk of a 
future CVD event are common. Often multiple pharmaceuticals taken concurrently are required to 
adequately reduce a patient’s absolute CVD risk.3, 4 Large pill burdens are not uncommon in CVD 
prevention, especially for those at high CVD risk or with comorbidities and are documented to 
negatively influence pharmaceutical adherence (not taking a pharmaceutical as prescribed). Non-
adherence to pharmaceuticals is a noted issue in CVD management, with adherence after a year 
reported being as low as 50%.5 Non-adherence to prescribed pharmaceuticals means the intended 
clinical result of the pharmaceutical is not realised and the patient's risk of having a cardiovascular 
event is not reduced.5, 6 Fixed-dose combinations (FDCs) that combine multiple pharmaceuticals into a 
single pill form are one identified method to reduce pill burdens and increase adherence.7 A variety of 
two to five-agent combinations are available for CVD.  
Economic evaluations aim to quantify the costs and consequences of an intervention, both monetary 
and otherwise and compare their ability to achieve a common goal. Information from economic 
evaluations should be considered by decision-makers in addition to clinical need, acceptability and 
suitability, to ensure that limited healthcare resource are expended as effectively and efficiently as 
possible.8 The pressure on healthcare resources could intensify in the coming years as a result of ageing 
populations. It is predicted that the future demand for healthcare is going to outweigh the availability 
of healthcare and that the retired population may be larger than the working-age population who 
make up the healthcare workforce and who are contributing to taxes that fund services including the 
healthcare system.9 
In the face of a significant burden of CVD, an increasing demand for healthcare resources, high usage 
of CVD pharmaceuticals for which adherence is known to be poor, in addition to potential 
improvements in clinical efficacy with the use of a FDC and the potential cost-savings as a result of 
reduced CVD related health service utilisation, it is worthwhile investigating whether the use of FDCs 
are a more cost-effective approach to reduce absolute CVD risk compared to the same 
pharmaceuticals taken separately (business as usual).2, 5, 7, 10 
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1.2 Study aims 
This thesis aimed to determine the health gains, cost impacts and cost-effectiveness of prescribing FDC 
for the prevention of cardiovascular disease (relative to the same agents taken as individual pills) by 
absolute CVD risk– initially in a selected group of New Zealand men aged 60 to 64 years.  
1.3 Study objectives  
The objectives of this study are:  
1. To summarise the current knowledge base of FDCs in the treatment and management of CVD 
in the literature using examples.  
2. To conduct a literature review of the cost-effectiveness of FDCs in CVD management globally 
and any meta-analyses of key parameters if required.  
3. To establish the health gains, health system costs and cost-effectiveness of a two-agent CVD 
prevention pharmaceuticals compared to individual pills – starting with a select group from 
the New Zealand population and by strata of absolute CVD risk.  
4. To determine whether health gains, costs and cost-effectiveness differ by a variety of factors 
considered in scenario and sensitivity analyses.  
1.4 Thesis outline 
Chapter 2 details the burden of CVD, pill burdens and non-adherence and describes how FDCs could 
potentially help address the outlined issue. The first part of Chapter 3 aims to summarise the existing 
literature of CVD FDCs, the second section describes the results of a structured review regarding the 
cost-effectiveness of CVD pharmaceuticals. Chapter 4 outlines the modelling methodology and 
principles used in this thesis as we all as the selection of intervention inputs. Chapter 5 describes the 
results of this study. Chapter 6 discusses the results of this study, how they align with existing literature 
and what additional information this study adds. This Chapter also discusses the strengths and 
limitations of this study. Chapter 6 concludes this thesis by briefly summarising the findings of this 
study and considers potential implications for further research and for policy-makers.  
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Chapter 2: Background  
2.1 The CVD burden 
CVD poses a significant burden on the health of populations worldwide and New Zealand.2 In the early 
2010s, ischaemic heart disease and stroke were among the top three causes of death both globally 
and within New Zealand.1, 11 CVD is also associated with a significant morbidity burden with the health 
loss attributed to coronary heart disease (CHD) and stroke in the 2010s being the leading causes of 
health loss globally and the second and sixth causes of health loss respectively in New Zealand.12, 13 The 
burden of CVD disease in New Zealand disproportionately affects Māori (indigenous population) with 
CVD mortality almost two times greater for Māori than non-Māori.1 Although the majority of the CVD 
health burden is experienced by those aged over the age of 40, the CVD health burden for Māori 
typically begins to occurs at earlier ages.1 
The health burden of CVD results in a significant financial burden on the government-funded health 
system to provide the primary and secondary care services required by populations with CVD or at 
high risk of having a CVD event. In a report by the National Health Committee in New Zealand,14 CHD 
was estimated to cost NZ$228 million while stroke, including rehabilitation cost, cost approximately 
NZ$114-120 million in 2011/12.14 These costs do not represent the additional costs that arise from 
various community support services. Further costs to the government-funded health system are 
incurred by hospitalisations attributed to CVD risk factors (eg, to stabilise very high blood pressure 
(BP), subsidising CVD pharmaceuticals and subsidising general practitioner (GP) visits).14  
At a societal level, the burden of CVD is also evident. The societal costs of CVD incorporate income, 
taxation and productivity losses associated with an individual taking time off work, prematurely 
retiring or dying before ending paid employment as a result of CVD.8 The cost associated with 
individuals receiving government support due to CVD illness is also considered as a societal cost of 
CVD. An Australian-based study found the annual cost associated with labour force absenteeism due 
to CVD in the 45 to 64-year age group in 2009 was AU$1.1 billion in loss of income, AU$85 million in 
taxation losses and AU$225 million in Government support, when compared to the cost and income if 
the same group participated in the labour force to the same degree as those without CVD.15 New 
Zealand data shows similar patterns with employment rates and individual earnings significantly lower 
in the six months following a stroke or CHD event, whereas income support increased.16 
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2.2 Addressing the CVD burden  
Globally and for New Zealand, the burden of CVD is significant.2 If age-specific trends in CVD incidence 
(where CVD rates increase as age increases) do not decline substantially, the burden of CVD has the 
potential to increase because the number of people living in older age groups is increasing due to 
ageing populations.17, 18 Previous research has demonstrated that reducing the burden of CVD is likely 
to reduce costs and improve the health and well-being of the New Zealand population.19, 20 The large 
burden of CVD is primarily due to the high prevalence and cost of modifiable risk factors.1, 13 
Internationally and within New Zealand, there are many interventions that aim to reduce the overall 
burden of CVD by addressing one or more CVD risk factors.2 The focus of this thesis is the use of CVD 
pharmaceuticals that target CVD risk factors for the primary prevention of CVD. 
2.3 Pharmaceuticals in CVD and absolute CVD risk  
Pharmaceuticals common in the management of CVD are anti-hypertensives which act to reduce 
elevated BP, statins which aim to reduce high blood cholesterol levels and aspirin, an anti-coagulating 
pharmaceutical which prevents blood clots that have the potential to result in a CVD event.21 In 2017, 
four of the ten most prescribed medicines in New Zealand were for CVD. Atorvastatin (statin) and 
aspirin (anti-coagulant) had 1.26 million prescriptions each, while metoprolol succinate and cilazapril 
(both anti-hypertensives) had 0.97 and 0.79 million prescriptions respectively.10  
Historically, the treatment and management of CVD considered each CVD risk factor in isolation, with 
clinicians intervening only if an identified risk factor was above a defined arbitrary threshold.22 More 
recently, CVD treatment and management has moved to focus on an individual’s absolute CVD risk.22 
In contrast to the historical risk approach, the absolute CVD risk approach considers an individual’s risk 
of having a CVD event by evaluating all major CVD risk factors together. This approach acknowledges 
that CVD is a complex disease with several interrelated risk factors that together influence an 
individual’s risk of a CVD event. Furthermore, the approach acknowledges that CVD risk factors and 
hence absolute CVD risk occur on a spectrum where even slight increases in risk are noteworthy. 
Importantly, the approach allows the subsequent action to mitigate an individual’s CVD risk to be 
proportional to the overall level of risk identified.23, 24 
Based on the above holistic understanding of CVD, the renowned Framingham Heart Study23, 24 
developed CVD risk equations that synthesise an individual’s absolute CVD risk or the probability that 
an individual will have CVD event in a given period. These risk equations, commonly presented as 
charts or as software programs, provide an easy to use, summative measure which can be used to 
identify those at increased risk of a CVD event and guide a treatment decision, ultimately preventing 
CVD events.23, 24 New Zealand specific risk equations have been available since the early 1990s.21, 25 
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Updated New Zealand CVD equations for the primary prevention of CVD were released in February 
2018.3 The new guidelines were generated from a large body of New Zealand specific data and 
incorporated additional variables. The updated guidelines aimed to improve the specificity of the risk 
equations, particularly for Māori, Pacific and South Asian populations.3  
The new risk equations collate the following variables and generate a probability of a CVD event 
occurring in the next five years: age, gender, ethnicity, New Zealand deprivation quintiles (NZDEP), 
family history of CVD and diabetes, patient medical history of CVD including atrial fibrillation, diabetes 
(and diabetes duration), renal function, smoking, blood pressure, blood cholesterol, blood glucose, 
body mass index and CVD pharmaceutical use (anti-hypertensive, statin and anticoagulants). The new 
variables are in italics.3 Screening for CVD is recommended for the general population from the age of 
45 for men and 55 for women.3 This age range has not changed from the previous guidelines.21 CVD 
risk screening for Māori, Pacific and South Indian populations is recommended from the aged of 35 for 
men and 40 for females, acknowledging different CVD risk profiles.3 This age range is five years younger 
than the screening ages recommended in the 2012 guidelines.21 Individuals with a five-year absolute 
CVD risk score of 5-10% are advised to consider the use of anti-hypertensives and lipid-lowering 
pharmaceuticals (2012 guidelines five-year absolute CVD risk score of 10-20%) while individuals with 
a 15% or greater chance of a CVD event in the next 5 years are strongly advised to commence use of 
anti-hypertensive, statins and anticoagulants (2012 guidelines five-year absolute CVD risk score of 
20%+).3, 21 Overall, the 2018 primary care guidelines for CVD more accurately reflect the current CVD 
burden and suggest screening at younger ages for high-risk populations and early pharmaceutical 
intervention for everyone. The 2018 CVD guidelines became available just prior to the completion of 
this thesis, as a consequence, the absolute CVD risk scores discussed throughout this thesis relate to 
the 2012 CVD guidelines.21  
2.4 Pill burdens and pharmaceutical adherence  
Based on the results of the CVD risk assessment, individuals, especially those at high CVD risk, can end 
up taking four or more pharmaceuticals (multiple anti-hypertensives, a statin and an anticoagulant).21 
An individual’s pill burden or the total number of pills prescribed, may be increased further by the 
presence of co-morbidities that may also require pharmaceutical treatment (eg, diabetes). An 
Australian based study6 found that among a high-risk CVD population the median self-reported pill 
burden was seven different pharmaceuticals. On average four of the seven pharmaceuticals were for 
CVD.6 
A primary concern that arises when individuals are required to take numerous pharmaceuticals is a 
decline in adherence. Non-adherence to CVD pharmaceuticals (not taking prescription medicine as 
prescribed), is a noted issue in CVD management.26-28 A meta-analysis conducted by Naderi et al5 
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examined prescription refill data as a proxy for adherence to CVD pharmaceuticals from 20 
international studies and approximately 380,000 people. The study found that overall adherence to 
CVD pharmaceuticals − defined as 75% or more days covered by a prescription over a two year period 
− was only 57% (97%CI: 50−64%).5 This measure is likely to underestimate the true values as it does 
not consider those who collected their prescriptions but failed to take the pharmaceutical as 
prescribed. Another study that looked at the long-term adherence of anti-hypertensive 
pharmaceuticals used in phase four clinical trials found that after a year, approximately half of all 
patients had ceased taking their prescribed pharmaceutical altogether.29  
Non-adherence of pharmaceuticals is an important issue because if a pharmaceutical is not taken as 
prescribed the intended positive impact (clinical efficacy) of the prescribed pharmaceutical may not 
be observed. Reduced clinical efficacy means that the risk factor and the individual’s absolute CVD risk 
may not be reduced by the magnitude that could be achieved if the pharmaceutical was taken as 
prescribed, with consequence to the health of the individual and the healthcare system.30 For example, 
a study by Sokol et al in 200531 found that patients with hypercholesterolaemia and hypertension who 
had greater than 80% adherence (measured by access to prescribed pharmaceuticals) had significantly 
(statistically) lower all-cause hospitalisations than those who achieved less than 80% adherence. In 
addition, non-adherent patients had significantly higher medical costs than those with good adherence 
(albeit not statistically significant at all levels of adherence).31 
Non-adherence is complex and multifactorial. A large pill burden is just one factor among others 
(including patient’s age and education level as well as the patient-doctor relationship) which influences 
adherence.26-28 With non-adherence, a notable issue in CVD, several different methods to improve 
adherence have been explored. One method aimed explicitly at reducing pill burdens and simplifying 
complex pharmaceutical regimes with the aim of improving adherence, is combining several 
pharmaceuticals that are prescribed as individual pills into a single pill form. This is called a fixed-dose 
combination (FDC) (or single-pill combination).32 
2.5 Fixed-dose combinations  
Fixed-dose combination (FDC) pharmaceuticals, defined as a single pill containing two or more active 
agents that utilise independent biological pathways, is one method used to reduce a patient’s pill 
burden and increase adherence.32 FDCs are used in current clinical practice for the management and 
treatment of a variety of health conditions.  
The primary benefit of using FDCs is improved adherence when compared to the same pharmaceutical 
agents taken as separate pills. FDCs act to reduce an individual’s pill burden and simplify complex 
pharmaceutical regimens, consequently improving adherence of the remaining pharmaceuticals. 
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Improved adherence to pharmaceuticals is essential so that the intended clinical efficacy of the 
prescribed pharmaceutical can occur. The pharmaceutical components of FDCs typically have slightly 
lower dosages than the same components taken as separate pills. As a result, FDCs may be more 
tolerable and have fewer adverse effects than the same components as individual pills without 
compromising clinical efficacy.7 FDCs also have the potential to be lower in cost than the same 
components taken individually. The cost to individuals in terms of prescription costs and the cost the 
healthcare system in terms of the cost of dispensing pharmaceuticals may be less as only one pill needs 
to be dispensed or prescribed instead of multiple.7, 33 It is important to note that the cost reduction 
potential of FDCs are country-specific and depend on a number of factors including pharmaceutical 
price and availability, the proportion of pharmaceutical cost the user pays and the relative cost of the 
FDC pharmaceutical to its components, which is influenced by the availability of generic 
pharmaceuticals over brand-name pharmaceuticals that are generally more expensive.30  
FDC pharmaceuticals also have several limitations. Specifically, components of FDC pharmaceuticals 
are somewhat unmodifiable in their dosage (though of course some FDC tablets can potentially be 
halved). This is an issue if the clinician would like to modify the dosage of components within the FDC 
to tailor the pharmaceutical to better meet an individual’s risk profile or if the individual experiences 
adverse effects that can be attributed to one of the FDCs components.7 For this reason, FDCs for CVD 
are often suggested to be prescribed in the first instance and a change to appropriate monotherapies 
is recommended if issues arise. Contrary to strong existing evidence, concerns have been raised 
regarding the possibility that FDCs may result in individuals taking more pharmaceuticals than 
necessary and that reducing pill burdens by one or two pharmaceuticals (two pills into one pill) may 
have little overall significance.34, 35 There is also a possibility that individual components of the FDC 
may be cheaper than their FDC equivalent.7, 33 As mentioned above, the costs associated with FDC are 
country-specific and depend on a variety of factors. A summary of the benefits and limitations of FDCs 
is detailed in Table 1.  
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Table 1: Summary of criteria, potential advantages and disadvantages of FDC pharmaceuticals 
 
2.5.1 FDC use in treatment and management of health conditions 
FDC pharmaceuticals are widely used in modern medicine to treat and manage health conditions 
including infection with human immunodeficiency virus (HIV),36 malaria,36 tuberculosis (TB),36 
asthma,37 diabetes, 38 pain relief,39 fertility control,40 and CVD prevention.41 Common to all these health 
conditions is the need for several different pharmaceutical agents to be taken concurrently to achieve 
a common outcome be it pain relief, contraception, eradication of a malaria parasite or reduction of 
CVD risk. The consistent profile of pharmaceuticals used to treat these conditions makes their 
combination into a FDC rational. The common primary benefit cited for the use of FDC in these health 
conditions is improved adherence and simplified pharmaceutical regimes that consequently improves 
the clinical efficacy, tolerability and acceptability of the pharmaceuticals.36 Furthermore, in the case of 
asthma and hospital-based pain relief, FDCs allow better long-term management by strategically 
combining pharmaceuticals which act over different time horizons.37, 39 In the case of infectious 
diseases such as TB, HIV and malaria, improved adherence to treatment with FDCs is critical to reducing 
the evolution of pharmaceutical-resistant disease strains (via evolutionary processes).36 Additionally, 
some combinations have the unique feature of opposing the adverse effects created by the other. 
Many of these conditions pose a large burden on both the health of individuals and the healthcare 
Criteria • Contain two or more active pharmaceutical agents in a single pill form.  
• Active components of the FDC must work independently of one another  
Potential 
advantages 
• Typically improves adherence, consequent increase in clinical efficacy 
• Should simplify complex pharmaceutical plans and reduce pill burdens 
• May reduce dispensing costs (country-specific) 
• May be cheaper than the two individual components 
(pharmaceutical/country-specific) 
• May be cheaper for the user – one prescription cost vs multiple (country-
specific) 
• Should typically increase tolerability (reduced adverse effects) 
Potential 
disadvantages 
• The clinician is typically unable to adjust the dosage of individual 
pharmaceutical components (eg, when wanting to evaluate/remove an 
adverse effect that is likely to be attributable to an individual component) 
• Potentially more expensive than multiple individual pharmaceuticals 
(pharmaceutical/country-specific) 
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system, so the potential clinical effectiveness gains as a result of good adherence and the potential 
cost-savings associated with dispensing and prescribing fewer pharmaceuticals and reducing overall 
healthcare expenditure is significant.39, 7, 37 FDCs are seen to be particularly favourable in the treatment 
of infectious diseases in low-income countries that have a large burden of infectious disease and where 
cost of treatment is a barrier.36  
2.5.2 FDCs in CVD 
Analogous to the health conditions discussed above, the rationale for using FDCs in CVD prevention is 
reducing large pill burdens to increase adherence and consequently the clinical efficacy of the 
pharmaceutical.5, 7, 30 Guidelines internationally concur that two to three different anti-hypertensive 
pharmaceuticals are typically required to manage high blood pressure and that the same two to three 
anti-hypertensive in addition to a statin and aspirin are required to actively reduce high CVD risk.21, 42-
44 Despite the availability of several CVD-specific pharmaceutical agents spanning several 
pharmaceutical classes, the pharmaceutical profile for the treatment and management of CVD is 
largely similar. The consistent similarities of pharmaceutical profiles within CVD management, in 
addition to acknowledged issues with adherence, makes the use of FDCs in CVD management a rational 
development. Indeed, a variety of two- to five-agent CVD FDC pharmaceuticals have been developed 
and are used internationally. The usage and availability of CVD FDC varies dramatically between 
countries due to differences in health system organisation, pharmaceutical cost and pharmaceutical 
approval as well as the personal preference of clinicians.7, 45, 46 The current usage of FDC in the 
treatment of CVD FDC will be explored in greater detail in Chapter 3.  
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Chapter 3: Literature review  
This Chapter comprises of two literature reviews. The first review aims to summaries the existing 
published literature concerning CVD FDCs generally. The reviews begins with a discussion of the 
literature concerning FDC that address a single CVD risk factor and proceeds to discuss the available 
literature concerning the FDCs that address multiple CVD risk factors. The first review concludes by 
detailing the CVD FDCs that are currently available in New Zealand. The second review is more specific 
and aims to summaries the exisiting literature where the cost-effectiveness of CVD FDCs were 
examined. Two-agent FDC are explored independently to polypills.  
3.1 Literature review of CVD FDCs 
The use of FDCs in the treatment and management of CVD is not new. FDCs and their perceived 
treatment benefits were referenced in the literature for the treatment of hypertension as far back as 
the 1950s, with the first two and three-agent anti-hypertensive FDCs available in the 1960s.7 Coinciding 
with the move to consider absolute CVD risk approach in the early 2000s, FDCs that target two or more 
different CVD risks were developed. Specifically, a two-agent FDC that combines a cholesterol-lowering 
statin with an anti-hypertensive47 and a polypill, a four- to five-agent pill which combines several anti-
hypertensives with a statin and aspirin.48-50 
As has already been discussed in the Introduction of this thesis, the use of FDCs in CVD is a logical 
solution to reducing pill burdens. Several international guidelines, including European Guidelines on 
Hypertension, British Hypertension Society and Joint National Committee Seven for High Blood 
Pressure (JNC7), mention the use of two-agent anti-hypertensive agents where appropriate, 
acknowledging an adherence improvement as a result of simplifying pill regimens.43, 44, 51 Although 
international guidelines to date do suggest the use of several different classes of CVD drugs to best 
manage high CVD risk, multi-risk factor FDCs are not specifically mentioned.  
3.1.1 Single risk factor CVD FDCs  
Two-agent anti-hypertensive FDC  
Two-agent anti-hypertensive FDCs are currently the most common CVD FDCs in terms of their use and 
the number of combinations available internationally. Consequently, the body of literature concerning 
two-agent FDCs is vast. The positive impact that two-agent FDCs have on pharmaceutical adherence is 
reported in a meta-analysis by Gupta et al 2010.52 This analysis considered 15 randomised control trials 
(RCTs) and cohort studies (32,000 participants) and found that compliance (synonymous with 
adherence) among those taking a two-agent hypertensive was significantly greater than those taking 
the same two agents as individual pills (odds ratio (OR) = 1.21, 95%CI: 1.03 to 1.43). The study also 
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reported that individuals taking the FDC had greater benefit (in terms of lowering blood pressure) and 
fewer adverse events than those taking two-agents separately. These latter findings, however, were 
not statistically significant.52 An earlier review conducted by Bangalore et al in 200753 mirrored the 
findings of Gupta et al 201052 in finding two-agent anti-hypertensive FDCs reduced the risk of non-
compliance by 24% (relative risk (RR) = 0.76, 95%CI: 0.71 to 0.81).53 To date, the studies by Bangalore 
et al and Gupta et al appear to be the only meta-analyses published that investigate two-agent anti-
hypertensive FDCs compared to the same agents taken as separate pills.54 
Further to improvements in adherence and clinical efficacy, two-agent anti-hypertensive FDCs also 
demonstrate a cost-saving potential if the price to the consumer and the government to obtain and 
dispense the FDC is cheaper than the cost of two individual pills. This cost-saving potential is 
demonstrated in Akazawa and Fukuoka 201355 who monitored patient pharmaceutical expenditure 
over a policy change that made FDCs prescriptions more accessible in Japan. This is also the case with 
Stankus et al 200956 who investigated the potential cost savings accrued in a hypothetical scenario 
analysis should a proportion of Canadians currently taking one of two combinations of anti-
hypertensives switch to the corresponding FDC. Both studies found annual pharmaceutical 
expenditure would decrease significantly should more people take FDCs compared to combination 
monotherapy (Akazawa and Fukuoka: a 17% decrease in pharmaceutical expenditure; Stankus et al for 
a 100% population switch: Can$45 million saving annually). Akazawa and Fukuoka also noted an 
increase in expenditure for some individuals who moved from monotherapy to the FDC as the FDC was 
more expensive than a single pill.55 
The other significant benefit cited for the use of FDC is the longer-term gains in terms of reduced 
healthcare utilisation and associated health system costs that are a result of improved blood pressure 
control due to FDC use. A study conducted by Yang et al 201057 used a retrospective cohort design to 
investigate differences between those taking a variety of two-agent anti-hypertensive FDC compared 
to two separate pills in the United States. Further to observing a statistically significant improvement 
in adherence among those taking FDCs, the study found that those whose treatment was initiated with 
a FDC had significantly fewer all-cause hospitalisations and emergency department visits than those 
treated with the same components as separate pills. Those taking the FDCs had 29% fewer CVD 
hospitalisations that those on the same pharmaceutical as separate pills (incident rate ratio= 0.71, 
95%CI: 0.69 to 0.72). Furthermore, FDC initiation was associated with a significant reduction in all-
cause medical costs and CVD-related medical costs, with the latter reducing by US$180 per patient for 
those initiated on FDC compared to separate individual pills in the six months following initiation of 
treatment. This reduction was despite the significant difference in pharmaceutical costs that were 
higher for those in the FDC group compared to those taking the same components taken as separate 
pills.57 Results of several other studies echo the results of Yang et al 2010, however, it must be noted 
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that the results are not always statistically significant and that multiple different FDCs were studied.30, 
58 
Three-agent anti-hypertensive FDCs 
Acknowledging that many people may require up to three different anti-hypertensive pharmaceuticals 
to adequately control of their elevated blood pressure, three triple anti-hypertensive FDCs have been 
developed. The combinations combine valsartan, olmesartan or aliskiren with amlodipine and 
hydrochlorothiazide. To date all three combinations are approved in the United States,59 the 
combination with valsartan is approved by the European Medicine Agency,60 and the olmesartan 
combination is approved in Australia.61 Currently, no triple anti-hypertensive FDC is available in New 
Zealand. The body of evidence surrounding the clinical efficacy and adherence advantage of triple anti-
hypertensive FDC therapy is limited. Several studies demonstrate that the FDC has superior clinical 
efficacy in terms of blood pressure reduction compared to two of the agents as monotherapies.62-64 
Studies comparing the FDCs directly to its monotherapy combinations as well as studies investigating 
the possible difference in adherence and long-term CVD endpoints are lacking. Further research in this 
area is required. 
Two-agent lipid-lowering FDCs 
FDCs that combines a statin with ezetimibe, a drug that limits cholesterol absorption from the small 
intestine, has recently become available following the successful use of the two agents as a 
monotherapy combination to reduce cholesterol among individuals who fail to adequately reduce their 
cholesterol with lifestyle changes and statins alone. A body of literature supports the clinical efficacy 
of this FDC compared to a statin alone,46, 65 but as with the triple anti-hypertensive FDCs, further 
research into the FDCs impact on adherence, longer-term clinical endpoints and costs is required. 
Presently the combination of ezetimibe and a statin (either simvastatin, atorvastatin or rosuvastatin) 
are available in the United States,59 Europe,60 and Australia.61 The FDC combination of simvastatin with 
ezetimibe (Zimybe) is currently available in New Zealand with a Special Authority.66  
3.1.2 Multi-risk factor FDCs  
The recent introduction of multi-risk factor CVD FDCs has revitalised interest in CVD FDCs. In 2017, the 
Cochrane Collaboration41 conducted a review of the effect of FDCs that contained at least one anti-
hypertensive and one lipid-lowering component for the prevention of atherosclerotic CVD. The study 
aggregated 13 RCT (total participants=9059) which compared two to five agent CVD FDCs to usual care, 
placebo or equivalent monotherapy. Overall, the review found that the CVD FDCs significantly reduced 
systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C) levels (moderate 
evidence quality) and that adherence improved by 44% (26% to 65%). No statistically significant 
difference in mortality and CVD event rates were observed in this review, but this could be due to the 
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short duration of the trials, which would not capture the long-term effects of treatment. Treatment 
with a FDC was associated with a slight increase in the risk of an adverse event (RR = 1.6, 95% 
confidence interval (95%CI): 1.09 to 1.25). Overall the reviewers evaluated the quality of the evidence 
to be low and the heterogeneity of the included studies was high. Further longer-term research is 
required to see if the observed changes in risk factors result in changes to the risk of CVD events and 
CVD-mortality.41 Meta-analyses that consider more homogenous FDCs (in terms of type and number 
of active components) would also be desirable.  
Anti-hypertensive with a statin two-agent FDCs 
FDCs that combine an anti-hypertensive with a statin are currently the most available and utilised 
multi-risk factor FDC for CVD prevention. The combination of amlodipine, a calcium channel blocker 
(CCB) with atorvastatin is currently available in Australia61 and the United States.59 To date, no such 
FDCs are available in New Zealand.  
Several RCTs to date have been conducted demonstrating the significant effect that the 
amlodipine/atorvastatin FDC has on lowering blood pressure and cholesterol levels simultaneously. 
Erdine et al 2009,67 for example, conducted a 14-week non-comparison RCT that included participants 
from 27 countries (Latin America, Middle East, Africa and Asia-Pacific) who ranged from low to high 
CVD risk. The study observed significant reductions in mean SBP and diastolic blood pressure (DBP) 
after 14 weeks (-20.2 and -11.5 mmHg respectively) as well as total cholesterol levels which reduced 
by 21.6%. Adverse events experienced by all study participants that resulted in the discontinuation of 
therapy were relatively low (3.6%). Excluding those with known CHD and/or diabetes mellitus, the 10-
year Framingham CVD risk decreased from 13.4% to 6.2% over the 14-week study period.67 Further to 
the observed improvement in clinical efficacy with the use of the FDC amlodipine with atorvastatin, 
adherence was also greatly improved. 
Another study by Patel et al 200968 found that those who took this type of FDC were 1.95 times as 
likely to be adherent (defined at >80% pill days covered (PDC)) than those taking the component 
separately over six months. Adherence was still markedly greater among those taking the FDC 
compared to two separate pills at one year (adjusted OR = 2.71, 95%CI: 2.46 to 2.99). A similar increase 
in adherence with this FDC was observed in an Australian study by Simons et al69 and an American 
study by Chapman et al.70 The study by Chapman et al in 201070 was a retrospective cohort study using 
administrative claims data in the United States. The study identified individuals taking either a CCB like 
amlodipine or a statin like atorvastatin, who during an index period were switched to the single pill 
FDC or had either a CCB or a statin added to their regimen (resulting in them taking the same two 
components as separate pills). In addition to finding that those taking the single pill FDC were 4.7 times 
as likely to be adherent (proportion of days covered by a prescription greater than 80%), the study also 
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found that those taking the FDC who were adherent experienced fewer CVD events than those taking 
a CCB and a statin separately (Hazard ratios: 0.79, p<0.05; 0.61, p<0.05 respectively when compared 
to non-adherent CCB and statin separately).70  
‘Polypill’ for CVD prevention 
This type of polypill is a CVD FDC that combines aspirin and a statin with several different anti-
hypertensives that was suggested as a method to prevent CVD in the early 2000s. Yusuf et al 200271 
suggested the combination and the following year Wald and Law published a study that boldly 
predicted that if everyone aged 55 years and older with existing CVD was treated with their six-agent 
‘polypill ’ (aspirin, a lipid-lowering agent, folic acid and 2−3 anti-hypertensives), then CHD and stroke 
deaths would reduce by 88% (95%CI: 84 to 91%) and 80% (95%CI: 71 to 85%) respectively. They argued 
that population-wide treatment based on CVD alone would benefit a third of the population, while 
8−15% would experience adverse effects.72  
Since Wald and Law’s publication,72 several RCTs have been conducted internationally to investigate 
the benefit of a ‘polypill’ for CVD prevention. The results from three major polypill RCTs, namely, 
IMPACT,50 UMPIRE48 and Kanyini-GAP49 that consider a four-agent polypill (aspirin, statin and two anti-
hypertensives) are summarised in Table 2. Although all three studies show major improvements in self-
reported adherence when compared to usual care, the effect of the ‘polypill’ on primary clinical 
endpoints such as SBP or DBP and LDL cholesterol is minimal. Furthermore, no effect on CVD events 
has been observed, possibly due to most studies not containing enough power or duration to detect a 
significant difference. Adverse effects experienced by those on the polypill appear to be greater than 
those on usual care which could have contributed to the trial discontinuation rates.48-50 
Internationally, the benefit of the CVD polypill to effectively reduce CVD risk is debated. Primarily, 
countries and organisations are concerned with the idea of mass population-level pharmaceutical 
treatment and the associated risk of removing the focus from individual health changes and over 
medicating a population. Furthermore, despite improved adherence, short-term gains (blood pressure 
and LDL reduction) and long-term gains (reduced CVD events, hospitalisations and costs) are yet to be 
observed. Currently, only a three-agent polypill containing aspirin, a statin and an anti-hypertensive 
has been approved for secondary CVD prevention in 15 European countries (including Spain, Sweden, 
Finland, Germany and Austria) and Chile as a direct substitution for those already taking the polypill 
components as monotherapy. Although approved, the polypill is only marketed in Germany, Greece, 
Romania and Spain.73 The polypill has been submitted for approval to appear on the World Health 
Organization (WHO) essential medicine list in 2013 and 2015 and to the PHARMAC Pharmaceutical 
Schedule in New Zealand in 2016. On all occasions, the submission was declined for the reasons 
described above. In addition, concern was raised regarding the effect the polypill will have on an 
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individual’s pill burden with PHARMAC quoting “…the convenience of taking one FDC polypill (instead 
of multiple single pills) would be minimal in those patients who are already taking a number of 
pharmaceuticals for multiple comorbidities”.74 Further research is currently being conducted and is 
required in this area to add data about the advantages/disadvantages of polypill use. 
Table 2: Summary of three major 'polypill' RCTs (Kanyini-GAP, IMPACT, UMPIRE) 
 
3.1.3 New Zealand CVD FDCs 
In New Zealand, in 2017 there were six, two-agent FDCs available on the PHARMAC Pharmaceutical 
Schedule 2017 (Table 3) These six FDCs cover four pharmaceutical classes, five contain two anti-
hypertensive components and one contains two lipid-lowering agents.66 Australia, by comparison, had 
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Table 3: FDC available in New Zealand 2017 





Cilazapril (5 mg) with hydrochlorothiazide (12.5 
mg) 
Accuretic 10 Quinapril (10 mg) with hydrochlorothiazide 
(12.5 mg) 







Losartan potassium (50 mg) with 




Frumil Amiloride hydrochloride (5 mg) with 
furosemide (40 mg) 
Moduretic Amiloride hydrochloride (5 mg) with 
hydrochlorothiazide (50 mg) 
Cholesterol 
Lowering 
Zimbye Ezetimide (10 mg) with simvastatin (10, 20, 40, 
80 mg) 
Source: PHARMAC 201766 
3.1.4 Conclusions 
The current body of evidence suggests that, in general, CVD FDCs are likely to result in superior 
adherence and clinical efficacy compared to two agents taken separately, usual care or placebo. 
Furthermore, there is some evidence to suggest that improved adherence and clinical efficacy should 
result in longer-term reductions in: CVD incidence and mortality, CVD-related hospitalisations and 
CVD-related hospital and pharmaceutical expenditure. Literature supporting the clinical efficacy of 
CVD FDCs is vast due to the requirement of clinical trials to bring new pharmaceuticals to market. 
However, further research is required to add evidence to the use of FDCs as a method to improve 
adherence, reduce CVD disease burden and reduce costs. Future research that compares CVD FDCs to 
the same components as monotherapies, rather than a single pharmaceutical or another 
pharmaceutical regime, would be desirable as switching people currently on the monotherapy 
components to the corresponding FDC is one of the primary aims of a FDC (second to initiating people 
on combination therapy). RCTs may fail to observe the real-world effectiveness of the FDC on 
adherence due to differences between a trial setting and the real world. Short study durations that 
limited the ability to observe longer-term benefits, the funding of studies by pharmaceutical 
companies that have a vested interest the studies results and poor study design are limitations in the 
existing literature which should be noted and considered in all future research. It is also important to 
note that although the availability of FDCs in many countries is increasing, this does not necessarily 
translate to FDC uptake. Country-specific research that compares the cost of the FDCs with the costs 
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of the equivalent monotherapies, cost to the government, individual or another third party (ie, 
insurer), as well as physician and patient acceptability in prescribing an FDC, is also required.  
3.2 Literature review of the cost-effectiveness of CVD FDCs  
The terms listed in Table 4 were searched in OVID Medline (1946 to present [02/2017] with daily 
update), PubMed and Scopus in February 2017. In an additional search, the terms ‘cost-effectiveness’ 
AND ‘polypill’ AND ‘cardiovascular disease’ where searched in OVID Medline (1946 to present 
[02/2017] with daily update) and PubMed. Search results were restricted to those published from 2007 
onwards and those published in the English Language. Search results were downloaded to Endnote. 
Duplicate publications where identified and excluded. Further exclusions were made if the study FDC 
had greater than two pharmaceutical components, if the outcome was not deemed to be associated 
with cardiovascular disease (ie, HIV), if one or more of the FDC pharmaceutical components did not 
target a specific CVD risk factor (ie, not an anti-hypertensive, lipid-lowering or anti-platelet 
pharmaceutical) and if the study did not look at cost-effectiveness broadly (ie, studies that just 
compared costs and lacked an effectiveness component). Studies that summarised other studies such 
as reviews or opinion publications were also excluded. The reference lists of included publications were 
also examined to identify additional relevant research. An additional search was conducted in February 
2018 to identify any new publications.  
Table 4: Summary of literature review search terms 
Relating to cost-
effectiveness  
Cost-utility, effectiveness, cost-effectiveness, cost-benefit analysis, economic 
evaluation  
Relating to FDC Fixed-dose combinations, fixed combinations, FDC  
Relating to CVD Ischaemic heart disease, myocardial ischemia, coronary disease, coronary 
artery disease, coronary heart disease, cardiovascular disease, stroke, 
hypertensive, hypertension, anti-hypertensive agent, blood pressure, 
hypercholesterolemia, cholesterol  
 
After exclusions, five studies concerning the cost-effectiveness of two-agent FDCs were identified (two 
looked at an anti-hypertensive, lipid-lowering FDC, two looked at a two-agent anti-hypertensive FDC 
and one looked at a two-agent FDC of which both components were lipid-lowering) and nine 
publications concerning the cost-effectiveness of various polypills (aspirin, a statin and at least one 
anti-hypertensive). The literature concerning two-agent FDCs is explored separately to the literature 
regarding polypills. The identified publications are summarised in Appendix One.  
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3.2.1 Two-agent CVD FDCs 
Summary of identified studies  
Two of the identified studies investigated the cost-effectiveness of the FDC amlodipine (an anti-
hypertensive) with atorvastatin (a statin) (FDC AA) in a Korean primary prevention context. The earlier 
study by Liew et al 200975 considered the cost-effectiveness of a FDC AA compared to business-as-
usual using a lifetime Markov model. The model considered a Korean health system perspective and 
included Korean-specific health system costs, pharmaceutical costs and utility values. A decline in 
adherence in the first year from 100% to 69% was also incorporated in the model. The characteristics 
of the modelled population were informed by a national data collection which was used in conjunction 
with Asian specific CVD risk equations to determine the population’s risk of a having a CVD event. Blood 
pressure and cholesterol changes as a result of the FDC AA were modelled annually and modified the 
risk of having a CVD event. The study concluded that the FDC was likely to be a cost-effective means 
of preventing CVD with an incremental cost-effectiveness ratio of 7,773,063 South Korean Won (KRW) 
per QALY gained (US$ 5979 per QALY gained). The subsequent study by Park et al in 2015,76 considered 
the use of FDC AA compared to the same two agents as monotherapy for the primary prevention of 
CVD in a diabetic population (requiring both statin and anti-hypertensive therapy). A simple decision 
tree model was used in which the percentage of LDL goal attainment was determined based on 
differing rates of adherence. Both pharmaceuticals were assumed to be equal in efficacy. 
Pharmaceutical costs were Korean specific and related to adherence. The study concluded that the 
FDC AA was likely to be a cost-effective method of primary CVD prevention with the average cost-
effectiveness ratio for the FDC AA smaller (more favourable) than for that for A+A.  
Briseno et al 201077 considered the cost-effectiveness of the FDC ezetimibe and simvastatin compared 
with rosuvastatin (all lipid-lowering agents). The effectiveness component, percentage change in LDL 
cholesterol levels from baseline to week eight, was derived from a retrospective review of 296 patients 
records in a Mexican cardiology ward. The effectiveness of treatment was compared to the 
pharmaceutical cost of treatment. Briseno et al 201077 concluded that rosuvastatin was more cost-
effective at reducing LDL-cholesterol than the ezetimibe and simvastatin FDC with the cost per 1% 
reduction in LDL levels for rosuvastatin being approximately half that of the FDC.  
The study by Glasziou et al 201078 was different to the other identified studies as it considered the 
cost-effectiveness of FDC being accessed in a clinical trial. This “ADVANCE trial” was a multicentre RCT 
in type two diabetes patients who were randomised to receive either the FDC perindopril with 
indapamide or placebo (both anti-hypertensive agents) in addition to any other existing CVD 
pharmaceutical. Health-related quality of life was measured in the trial, but the difference between 
the trial arms was not statistically significant. The cost per death averted was alternatively considered 
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as the measure of effectiveness. Healthcare and pharmaceutical costs for the Australian subset of the 
trial were determined through record linkage. The study concluded that the FDC was likely to be cost-
effective with a cost per life-year saved of AU$49,000. One other identified study considered the cost-
effectiveness of a two-agent anti-hypertensive FDC. Kawalec et al 201579 investigated the cost-
effectiveness for indapamide with amlodipine FDC compared to the two agents as dual monotherapy 
for the prevention of CVD in Poland. The Markov model considered two situations, one in which the 
FDC was assumed to have better adherence and clinical outcomes, and one were both treatments had 
equal adherence. In both cases, the use of the FDC was cost-saving compared to equivalent 
monotherapies.  
Evaluation of identified studies  
The volume of literature concerning the cost-effectiveness of two-agent FDC combinations is small 
with just five studies identified. Comparison of each of the studies as an intervention for CVD 
prevention is difficult due to the notable difference in study rigour, modelling methodology and 
modelling principles.  
Liew et al 200975 was the only identified study that specifically investigated the cost-effectiveness of a 
FDC for the primary prevention of CVD and consistently used Korean specific information to inform 
model inputs. Glasziou et al 201078 also achieved consistency in model inputs with the majority of the 
model inputs informed by the ADVANCE trial. Both Glasziou et al78 and Park et al76 considered the use 
of FDC in a diabetic population. The population in Briseno et al77 was the least specific. The distinction 
between primary and secondary prevention was not clear in the studies by Glasziou et al,78 Park et al,76 
Kawalec et al,79 and Briseno et al.77  
FDCs are designed to be bioequivalent to their monotherapy components and improve adherence. As 
such, the appropriate study comparator should be the equivalent monotherapies. Differences in 
adherence should also be considered. Park et al 201576 and Kawalec et al 201579 were the only 
identified studies to consider monotherapies as a comparator and incorporate an adherence 
component. Liew et al's75 comparison of business-as-usual could be considered representative of 
equivalent monotherapies if the majority of included patient's business-as-usual included therapy with 
an anti-hypertensive and a statin. But it was not clear whether or not this was the case. Future 
economic evaluations of CVD FDCs should endeavour to have the equivalent monotherapies as the 
comparator and incorporate adherence.  
Effectiveness is a key component in cost-effectiveness studies. All five identified studies used different 
effectiveness measures (quality-adjusted life years (QALYs)75, 79, the percentage decrease in LDL 
levels77, percentage of LDL goal attainment76 and deaths averted78). QALYs are considered the gold-
stand of effectiveness measurement in health economic evaluation as they combine both the 
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morbidity and mortality burden of a condition and can be compared between other health conditions. 
Liew et al 200975 and Kawalec et al 201579 were the only studies to consider QALYs as an effectiveness 
measure. QALYs were measured in the study by Glasziou et al,78 but the difference between the trial 
arms was not statistically significant. The number of CVD and non-CVD deaths averted were 
alternatively used as the effectiveness component. Although all the effectiveness measures used in 
the identified studies provide useful information, they limit the comparability between the studies and 
limit the ability of decision-makers to evaluate different interventions to achieve a common goal.  
Although the pharmaceutical components in the FDCs evaluated are aimed at reducing CVD risk 
factors, the ultimate goal is reducing absolute CVD risk and the occurrence of CVD events (both fatal 
and non-fatal). The study by Liew et al 200975 used data on changes in surrogate CVD endpoints 
(reductions in blood pressure and cholesterol) to inform changes in absolute CVD and hence CVD 
events over a lifetime model horizon thus considering the long-term implications of FDC use. Glasziou 
et al78 considered the deaths averted over the five-year duration of the RCT with the difference in 
deaths averted evidence of the primary endpoints. Park et al76and Briseno et al77 only considered the 
change in surrogate markers over a one-year period. Accessing differences over a long enough time to 
observe changes in CVD events greatly strengthens the quality of evidence the study provides.  
Finally, the comparability of identified results to each other and the generalisability to the population 
beyond those considered in the studies is limited by the use of country-specific costs. The cost of 
pharmaceuticals and health services that were incorporated in each model are impacted by structure 
and funding of the healthcare system in each country. The Glasziou et al78 study used Australian 
specific costing information, which may be moderately generalisable to New Zealand as the healthcare 
system structure is relatively similar. Nevertheless, pharmaceutical costs are typically considerably 
lower in New Zealand compared to Australia.80, 81 The studies by Liew et al,75 Park et al76 and Glasziou 
et al78 were affiliated in sponsorship or personnel with pharmaceutical companies that manufactured 
the FDC being studied. It is reasonable to assume that both of these pharmaceutical companies have 
a vested interest in the outcome of both papers as it has the potential to influence the 
pharmaceutical's utilisation. As such interpretation and generalisation of the results of these studies 
should be done with caution.  
3.2.2 CVD prevention with polypills  
Summary of identified studies  
Nine studies investigating the cost-effectiveness of polypills for CVD prevention were identified in the 
literature. Two studies considered the cost-effectiveness of a five-agent polypill (aspirin, a statin and 
three anti-hypertensives) for the primary prevention of CVD. Bautista et al 201382 considered a 
hypothetical Latin America population with baseline characteristics informed by a multi-national Latin 
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America survey while the study by Zomer et al 201383 was conducted in Australia using microsimulation 
of patient-level data identified from an Australian database. Both studies used a Markov model in 
which the risk of experiencing a CVD event was determined by geographic specific CVD risk equations. 
Bautista et al 201382 compared the polypill to no-treatment while Zomer et al 201383 compared the 
polypill to multiple combinations of monotherapies. Changes in blood pressure and cholesterol levels 
within each of the pharmaceutical interventions were informed by the Indian Polycap study (TIPs) and 
consequently changed the risk of a CVD event. Both studies measured effectiveness in terms of QALYs 
and costs in terms of health system costs. In Bautista et al 2013,82 the polypill was estimated to cost 
US$50 per year, while Zomer et al 201383 assumed the cost was 25% less than the equivalent 
monotherapies. Bautista et al 201382 concluded that the use of the polypill for the primary prevention 
of CVD in those at high CVD risk (10-year absolute CVD of 15% or more) or those with abdominal 
obesity, was likely to be cost-effective. Zomer et al 201383 concluded the polypill may be an effective 
method of primary CVD prevention but not a cost-effective method with a cost of approximately 
AU$200,000 per QALY gained.  
A four-agent polypill (aspirin, a statin and two anti-hypertensives) was evaluated in four of the 
identified studies. Each of the identified studies were heterogeneous. Firstly, the study by Laba et al 
201484 considered the cost-effectiveness of the polypill compared to usual care for the secondary 
prevention of CVD by piggy-backing onto the Kaynini-GAP polypill RCT conducted in Australia. The 
study utilised the trial data and determined healthcare resource and pharmaceutical use through 
record linkage. The results of this study were primarily a cost-evaluation will no effectiveness 
component noted. The study concluded that the polypill had significantly lower pharmaceutical costs 
compared to usual care, but there was no difference in healthcare resource costs. The second study 
by Ito et al 201285 also considered the polypill as a secondary prevention measure and compared it to 
other adherence-improving interventions, namely, mailed education and disease management. A 
comprehensive lifetime Markov model of a hypothetical population of Americans aged over the age of 
65 was used, with changes in pharmaceutical adherence as a result of each intervention modulating 
the risk of a secondary CVD event. The model measured effectiveness in QALYs and the costs reflected 
intervention costs as well as the pharmaceutical costs and health system costs. The study estimated 
that the polypill alone had an average cost-effectiveness ratio of US$133,000 per QALY gained 
compared to usual care (no adherence-improving interventions). The polypill was the most expensive 
intervention per QALY gained except for the polypill in combination with disease management, which 
was more expensive. The study by Ndinjock et al 201186 looked at the cost-effectiveness of treating 
the population over the age of 40 with high CVD risk established by African-specific risk equations with 
the polypill compared to treating the population with high blood pressure or cholesterol with 
monotherapies. Anticipated reductions in CVD events for the polypill were taken from Wald et al’s  
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(2003) proposed polypill predictions. Costs were limited to pharmaceutical costs. Treating people 
based on CVD risk rather than addressing individual risk factors was considered to be the more cost-
effective method of CVD prevention when the number needed to treat and deaths averted were 
balanced against each other. Lastly, Megiddo et al 201387 considered the polypill for secondary 
prevention of CVD in India compared to equivalent monotherapies. The model method used was not 
clear in the publication. Nevertheless, the polypill was considered to be less costly than the equivalent 
monotherapies and no difference in adherence was noted. The study concluded that the polypill was 
a positive intervention for the secondary prevention of CVD resulting in a smaller cost per disability-
adjusted life-year (DALY) averted than the equivalent monotherapies.  
Becerra et al 201588 was the only study of those identified that looked at the use of a three-agent 
polypill (combined aspirin, an anti-hypertensive and a lipid-lowering component). The study compared 
the polypill to the same components taken as monotherapies for the secondary prevention of CVD in 
a primary care setting in the United Kingdom. The model considered a health system perspective 
Markov model with a 10-year time horizon. The authors stated that no clinical trial data about the 
polypill were available, so the clinical efficacy was assumed to be equal to the combination of elements 
taken individually. Inputs on adherence were derived from the UMPIRE study, a study which looked at 
four-agent polypill. In the base-case the polypill was assumed to improve adherence by 20% compared 
to monotherapies, preventing 15% more CVD events, resulting in an incremental cost-effectiveness 
ratio (ICER) of GBP8,200 per QALY. This was considered by the authors to be cost-effective.  
Ong et al 201489 and Ferket et al 201790 were the only studies identified in the literature review of this 
thesis to evaluate a polypill that did not contain aspirin. Both studies considered the cost-effectiveness 
of a polypill combining a statin and three anti-hypertensives. Ong et al 201489 study examined the 
effect of the four agent-polypill as a CVD prevention measure for indigenous Australians and compared 
to statins alone, two different anti-hypertensive classes taken as monotherapy and a healthy lifestyle 
intervention. Ferket et al 201790 alternatively compared the polypill as a population-wide intervention 
to treating CVD risk factors in patients with high CVD risk for the primary prevention of CVD in the 
United Kingdom. Ong et al 201489 considered a health system perspective, lifetime Markov model. The 
efficacy of the polypill was considered to be the multiplicative effect of the four individual components 
taken simultaneously and the cost was modelled to be between AU$50 and AU$500 per person per 
year. The polypill was found to be the most cost-effective option to reduce CVD in Australian 
indigenous population. At the highest proposed cost of $500 annually for the polypill, the intervention 
resulted in AU$13,000 per DALY averted when provided at mainstream GP clinics and AU$21,000 per 
DALY averted from indigenous health centres.89 Ferket et al 201790 used a comprehensive 
microsimulation model of 260,000 patients in the UK and included the disutility of taking a daily pill for 
the population of patients who would not otherwise need to take a CVD pharmaceutical. Ferket et al 
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201790 concluded that treating patients at high CVD risk was a more cost-effective method of primary 
CVD prevention than widespread use of the polypill. Although the polypill could be considered an 
effective strategy, it came at a higher cost.90  
Evaluation of identified studies  
The evidence concerning the cost-effectiveness of the polypill is small with just nine studies identified. 
Several of the identified studies support the hypothesis that the polypill is a cost-effective or cost-
saving method for reducing CVD risk, while others conclude it may be an effective but not cost-
effective strategy or not cost-effective at all. As with the literature identified for two-agent FDCs, there 
is a large degree of heterogeneity between the studies methods, models and principles which makes 
comparison difficult. Several studies considered the polypill for primary CVD prevention,82, 83, 89, 90 while 
others considered the use of the polypill for secondary care services.85, 87, 88 Several studies compared 
the polypill to various pharmaceutical components while other studies compared the polypill to other 
intervention strategies (ie, other adherence-improving interventions, risk factor approach). 
Furthermore, there was a breadth of countries studied, from developing countries in Latin America 
and Africa, to high-income countries including the United Kingdom, the United States and Australia. 
Not only does the risk of a CVD event differ between countries due to population differences in CVD 
risk factors, each country has a unique health system structure which influences the cost of health 
system services and pharmaceutical costs in the model.  
When considering the evidence of the cost-effectiveness of the polypill it is important to bear in mind 
the strength of evidence concerning the clinical efficacy of the polypill and the uncertainty surrounding 
the pharmaceutical cost of the polypill. As has been discussed in the previous section of this thesis, the 
clinical efficacy of the various polypills have only been considered in a small number of RCTs, which did 
not show any statistically significant difference in surrogate CVD endpoints despite improved 
adherence. Most of the identified studies used information from these RCT to determine the clinical 
efficacy of the polypill. Furthermore, at the time of this thesis, only a couple of polypill formulations 
were approved for use in a small selection of countries. Consequently, the price of the polypill if it was 
to be funded in the countries studied, was uncertain. Where the cost of the polypill was unknown in 
the identified literature, it was estimated based on assumptions that it would be equivalent or a 
proportion of the cost of monotherapy83, 85, 87 or based on expert opinion.82, 89 Although informing the 
efficacy of the polypill from the available trials and estimating the cost is reasonable given the limited 
information available, it is important to consider the effect these assumptions could have on the 
overall cost-effectiveness. The incremental efficacy and cost of the polypill to the comparator, be it a 
pharmaceutical or non-pharmaceutical intervention, is an important driver of the resulting cost-
effectiveness ratio and should be considered when interpreting and applying the results of cost-
effectiveness studies.  
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3.2.3 Conclusions  
Overall the literature concerning the cost-effectiveness of two-agent FDC and CVD polypill was sparse. 
The identified literature suggests that two-agent CVD FDC and CVD polypill could be a cost-effective 
method of addressing evident CVD burdens globally. However, overall the results are inconclusive. The 
identified literature is heterogeneous with large variation in modelling methodology, assumptions and 
principles, the comparison used and the source of model inputs. The heterogeneity between the 
identified studies makes comparison between the studies difficult. None of the identified studies were 
conducted in a New Zealand context. 
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Chapter 4: Methods  
This Chapter begins by describing why the FDC amlodipine with atorvastatin was chosen to be 
modelled in this thesis. Following a brief overview of the multi-state life-table model used in this thesis, 
the process of selecting the input parameters for both the intervention (FDC amlodipine with 
atorvastatin) and comparison (amlodipine and atorvastatin) are described. The Chapter concludes by 
describing the model scenario and sensitivity analyses that were carried out. 
4.1 Justification of study pharmaceuticals 
As previously discussed in this thesis, there are many different FDCs used in the prevention and 
treatment of CVD. After considering a range of possible two-agent FDCs to model, a decision was made 
to model the cost-effectiveness of a two-agent FDC that contained an anti-hypertensive component, 
amlodipine (a CCB) and a lipid-lowering component, atorvastatin (a statin). The FDC of amlodipine with 
atorvastatin will be referred to subsequently as FDC AA. The FDC AA is part of a relatively new and 
emerging area of CVD FDC pharmaceuticals that target multiple CVD risk factors simultaneously in a 
single pill form. This approach aligns with CVD guidelines internationally91 and in New Zealand21 which 
emphasise the importance of considering absolute CVD risk. The FDC AA is currently approved in 
several countries including the United States,59 Australia61 and several European countries including 
France, Spain, Poland, Austria, Finland and Hungary.92 However, the FDC AA is not currently available 
in New Zealand.66 The results of this research could therefore be useful for New Zealand decision-
makers considering the funding of the FDC AA in the future. In addition, atorvastatin was the sixth 
most prescribed medicine in New Zealand in 2016 with 1.2 million prescriptions, while CCBs like 
amlodipine had just over one million prescriptions in the same year.10 In New Zealand, it is estimated 
that 21% and 25% of Māori women and men aged 60 to 64 respectively are taking both a statin and an 
anti-hypertensive. The percentage is slightly lower for non-Māori with 12% of women and 15% of men 
estimated to take both a statin and an anti-hypertensive in 2013.93 These figures illustrate a significant 
population whom, if a FDC AA was shown to be cost-effective in the New Zealand context, could benefit 
from switching from two monotherapies to the FDC AA.93, 94 Accordingly, this thesis models the cost-
effectiveness of a scenario where individuals currently taking amlodipine and atorvastatin as two 
separate pills (A+A) switched to take the FDC AA (ie, to study the marginal health gain, costs and cost-
effectiveness of the FDC AA compared to A+A). 
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4.2 Ethics and funding  
The work in this thesis was conducted, funded and approved as part of a larger Health Research Council 
awarded to the Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme (BODE3) 
(project number 10/248, Ethics Committee reference number H13/049.).  
4.3 CVD multi-state life-table  
4.3.1 Model overview  
The cost-effectiveness of switching from the A+A to the FDC AA regimen was evaluated in this thesis 
using an existing CVD multi-state life-table (MSLT) model. This CVD MSLT model had been adapted 
from the validated Tobacco Control MSLT model that was developed previously by the BODE3 research 
group, with a number of related research publications.19, 95-97 The model functions to collate the 
morbidity and mortality experience in terms of QALYs as well as the health system costs that would 
accrue over the lifetime of a group of adult New Zealanders (specifically men aged 60 to 64 years) with 
or without a specified intervention. In this case, the intervention was the FDC AA compared to the A+A 
regimen.  
Conceptually, the CVD MSLT model has three interrelated life-tables. The central life-table of the 
model represented the life experience of the entire modelled population over time between three 
health states; ‘healthy’, ‘alive with CVD’ and ‘dead’ (see Figure 1). No transitioning between ‘alive with 
CVD’ and ‘healthy’ was permitted in the model to reflect the chronic, non-remitting nature of CVD. 
Running in parallel to the central life-table were two additional disease life-tables. These two disease 
lifetables stratify the movement to, within and from the ‘alive with CVD’ state to consider the 
experience of CHD (ie, alive with CHD) and stroke (alive with stroke) separately. (The three life-tables 
are conceptually outlined in Figure 2).  
 
 
Figure 1: CVD MSLT model showing state transitions 
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Within the central life-table, a proportion of the model population each cycle transitioned from a 
‘healthy’ state to an ‘alive with CVD’ state. This transition represents the sum of the transition from 
‘healthy’ to ‘alive with CHD’ or ‘alive with stroke’, which occurred simultaneously in the disease life-
tables. The transition from ‘healthy’ to ‘alive with CHD’ was informed by the incidence rate for CHD 
while the transition from ‘healthy’ to ‘alive with stroke’ was informed by the incidence rate for stroke. 
The incidence rates for stroke and CHD and therefore the transitional probability between the ‘healthy’ 
state and ‘alive with CHD’ or ‘alive with stroke” state were age, sex and ethnicity-specific (albeit in this 
version of the model, just for 60 to 64-year-old men).  
The transition from an ‘alive with CVD’ state to ‘death’ in the central life-table represented the sum of 
the transition from ‘alive with CHD’ and ‘alive with stroke’ to ‘death by CHD’, ‘death by stroke’ and 
‘death by non-CVD causes’. The transition from ‘alive with CHD’ and ‘alive with stroke’ state to ‘CHD 
death’ or ‘stroke death’ was informed by the case-fatality rates for CHD and stroke respectively. Death 
from other causes was informed by the New Zealand population mortality rate, which was adjusted 
for CVD deaths to avoid double counting. The adjusted background mortality rate also informed the 
transition probability from the ‘healthy’ state to ‘death by non-CVD causes’. The case-fatality rates for 
stroke and CHD, in addition to the background mortality rate, were also all age, sex and ethnicity 
specific.  
The annual incidence and case-fatality rate (CFR) for CHD and stroke decreased by 2% annually in the 
model to reflect the ongoing decline in CHD and stroke. The proportion of the population residing in 
each health state at any one time was representative of the disease prevalence and was a function of 
the incidence rate (inflow) and CFR (outflow) for each disease. Further details on how the CVD disease 
incidence rates, prevalence and CFRs were calculated from New Zealand epidemiological data using 
DISMOD II is outlined in the supplementary material of the tobacco MSLT.19  
Essentially, the entire model cohort is represented in the central life-table, but the experience of those 
who experienced CVD (either stroke or CHD) will be captured in the CHD and stroke life-tables that are 
run in the model simultaneously. It is important to note that it was possible for individuals to exist in 
more than one disease life-table in the model at any one time (hence the name MSLT). For example, it 
is possible for someone to have prevalent CHD disease and stroke simultaneously. The transitional 
probabilities are adjusted to take this into account. The incidence and case-fatality rates are also 
adjusted to reflect recurrent stroke or CHD events. The model only considered the life-tables for stroke 
and CHD. As a result, the benefit of an intervention on conditions other than CHD and stroke are not 




Figure 2: Systematic representation of the CVD MSLT health states, transition probabilities and 
health system costs. 
4.3.2 Health impact (QALYs gained) 
The health impact or time spent in poor health was quantified in the model by QALYs. QALYs aggregate 
changes in mortality (number of years of life lived) and morbidity (health associated quality of each 
year lived) experienced by a population. Mortality is informed by changes in life-expectancy while 
morbidity is informed by disability weights. Disability weights aim to quantify the severity of disability 
experienced by a condition on a scale of zero (full health and no disability), to one (severe disability 
equivalent to death). Primary prevention interventions, like the one in this thesis, involve modelling 
with the aim of reducing the incidence of disease and consequently both disease morbidity and 
mortality. Nevertheless, the QALYs gained by a primary prevention intervention for CVD are generally 
influenced more by a gain in life expectancy rather than a quality of life improvement.  
The disability weight for those in the central life-table were determined by dividing the total years of 
life lived in disability from the 2006 New Zealand Burden of Disease Study (NZBDS) (2011 projected 
estimates) by the total population size. The resulting disability weight were then adjusted to avoided 
double counting of CVD morbidity. Disability weights in the two CVD life-tables were determined by 
dividing the years of life spent in disability with CHD or stroke by the prevalence of the respective 
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disease. The calculated annual disability weights were assigned to each health state and were accrued 
by the proportion of the population residing in each health state with each annual model cycle. All 
disability weights in the model were age and sex-specific and were accrued with each annually model 
cycle. The model used a disability weight for non-fatal stroke of 0.226 and 0.081 for non-fatal CHD.  
4.3.3 Costs 
The CVD MSLT model takes a health-system perspective. Consequently, the model considered costs 
associated with the health system in the treatment and management of CVD disease. The model 
benefited from rich costing and health event data from the New Zealand HealthTracker database which 
records all health events and costs that occur as part of the publicly funded health system in New 
Zealand.98 The unit resource costs linked to each health event included inpatient hospitalisation, 
outpatient attendance, laboratories usage, as well as pharmaceuticals. Primary care costs were limited 
to average capitation funding allocated to an individual to attend a GP. Individual’s in the database 
were assigned a unique identifier, which allowed their health journey and their associated healthcare 
costs to be collated. The information provided by HealthTracker, although comprehensive, still has 
limitations. Notably, data on palliative care data is currently absent as is information on any health 
events that occurred in the private healthcare sector (approximately 17% of New Zealand health 
expenditure). Both limitations where accounted for in the model by price scaling (for further 
information see supplementary text two from Blakely et al 2015).19  
Data from HealthTracker captured between 2006 and 2010 was used to determine the average annual 
health system cost by age and sex associated with four distinct periods in the life course of the model 
population.99 Firstly, the proportion of the model who were ‘alive’ in the model (‘healthy’ state or ‘alive 
with CVD’ state) at each annual model cycle were assigned an annual health system cost (Costx) (Figure 
2). In addition to the base cost (Costx) further costs were applied to:  
• The proportion of the population in the first year of incident CVD (CHD or stroke) to represent 
the additional cost associated with diagnosis and treatment initiation (CostX+A);  
• The proportion of the population with prevalent CVD (CHD or stroke) who were not in the first 
year of having the disease, nor in the last six months of life, to represent the ongoing cost 
associated with CHD or stroke events (CostX+B) 
• The proportion of the population in last six months of life (CHD, stroke or generally) (CostX+C) 
to represent the increased use and cost of healthcare associated with end of life. 
All costs were in 2011 New Zealand dollars. Due to the nature of the MSLTs, it is important to note that 
the above costs were not always mutually exclusive. For example, it was possible to have a prevalent 
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stroke and be in the first year of a CHD diagnosis. To avoid double counting and the overestimation of 
healthcare costs, this was adjusted for by considering the number of people who would experience 
this (see Kvizhinadeze et al 201699 for further information). 
4.3.4 Model population  
The existing BODE3 Tobacco Control MSLT which was adapted to create a CVD MSLT model, modelled 
the entire New Zealand population alive in 2011 (the baseline year of the model) based on 2006 New 
Zealand Census data projected estimates. The CVD MSLT model adaption currently considers a subset 
of this original population, namely, men aged 60 to 64 years who in 2011 were alive, did not have 
prevalent CVD (including stroke and CHD) and who were not taking any CVD preventive 
pharmaceuticals. Adapting the model to include only men aged 60 to 64 years is only the first stage of 
the model’s development. The group of men aged 60 to 64 years was chosen as a starting point 
because it is an age-group who experience a significant burden of CVD at a large cost to both the health 
of individuals and the healthcare system.1, 13 Interventions to reduce absolute CVD risk in this age-
group, therefore, have the potential to improve population health and reduce health expenditure. 
Furthermore, improving the health of this age-group could increase their longevity and the 
productivity of the New Zealand workforce to the benefit of workers themselves (if they wish to keep 
working after age 65 years) and to society as a whole. Table 5 shows the model population numbers 
by CVD risk strata.  
4.3.5 CVD risk strata  
Within the central life-table and subsequent CVD life-tables, the study population was stratified into 
groups of five-year absolute CVD risk (ie, the risk of having a CVD event in the next five years). The 
purpose of this division was to consider the health gains, costs and cost-effectiveness of treatment 
within each risk group, acknowledging that baseline absolute CVD risk could influence the capacity to 
benefit from treatment and the resulting cost-effectiveness ratio. The division of the population into 
five-year absolute CVD risk strata was informed by the proportions of individuals at each level of risk 
in a publication by Knight et al in 2017.93, 94 Knight et al used New Zealand specific data and CVD risk 
equations to simulate absolute CVD risk strata in a synthetic New Zealand population. The CVD risk 
proportions were applied to the original adult population considered in the MSLT model as part of the 
model's adaption to the CVD MSLT model (with this process being performed for other, still 
unpublished, BODE3 work on the cost-effectiveness of triple therapy for preventing CVD). The 
incidence rate of having a CVD event was adjusted to be specific to each CVD risk strata. For further 
information on the division of the population by absolute CVD risk see Appendix Two.   
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Table 5: Model Population numbers by CVD risk strata  
(men in New Zealand aged 60 to 64 years with no prior CVD and not on CVD preventive 
medications) 
CVD Risk Strata Non-Māori Māori 
Risk Stratum 5: >20% (highest risk) 58 42 
Risk Stratum 4: >15%, 20%  273 162 
Risk Stratum 3: >10%, 15% 1941 739 
Risk Stratum 2: >5%, 10 20,194 2500 
Risk Stratum 1: >0%, 5% (lowest risk) 37,464 837 
Risk Strata Combined 59,930 4280 
 
4.3.6 Model baseline  
As in the tobacco MSLT, the baseline scenario of the CVD MSLT represented ‘business as usual’ (BAU) 
(do nothing). Reconfiguring the model baseline to represent the intended BAU of this thesis, the A+A, 
regimen was not possible due to the time constraints of this thesis. Consequently, the model was set 
up to run twice, once with the model intervention inputs for A+A compared to BAU and a second time 
with the intervention inputs for FDC AA compared to BAU. The resulting QALY gains and health system 
costs from FDC AA compared to BAU were then subtracted from the QALYs gained and the health 
system costs from A+A compared to BAU. The implications of this are discussed further in the 
Discussion, Section 6.5.2.  
Table 6 outlines the parameters, sources and parameter uncertainty of the model inputs that 




Table 6: Baseline CVD MSLT model parameters 
Input 
parameter 
Source Heterogeneity  Uncertainty Time trend Distribution 
Population Statistics New 
Zealand (SNZ) 
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4.3.7 The intervention (FDC AA compared to A+A)  
The key intervention inputs in the model were the intervention (pharmaceutical regimen) uptake and 
regimen adherence and clinical efficacy. The selection of model inputs for the intervention A+A and 
the FDC AA is discussed in detail in Section 4.4. In the model, intervention uptake determined the 
proportion of the baseline model population who would receive either pharmaceutical intervention. 
Pharmaceutical adherence then influenced the proportion of the uptake population who receive the 
additional clinical benefit of being prescribed either pharmaceutical intervention. Uptake was 
determined at the start of the model while adherence changed annually over the five-year intervention 
period. The clinical efficacy of either intervention was associated with the proportion of the population 
who were adherent and modulated the incidence of stroke and CHD. Changing the incidence rate of 
stroke and CHD influences the proportion of the population with prevalent CVD disease and 
consequently CVD deaths. Measuring the difference in the health gains (QALY) and costs that accrued 
over the modelled populations lifetime as a result of differences in uptake, adherence and clinical 
efficacy between the FDC AA and A+A was the focus of this thesis.  
The model considers annual transitions between health states, a five-year intervention period and a 
lifetime horizon. During the five-year intervention period, the adherence rates and clinical efficacy for 
the proportion of the population who receive either intervention (uptake) were applied. The annual 
pharmaceutical cost for each intervention accrued over the intervention period as did the QALYs 
gained and the health system costs associated with the proportion of the population residing in each 
health state. After five years, the intervention effect was assumed to be turned off (ie, no one in the 
population receives the benefit or cost of taking either intervention – as at this point it is likely that 
patients will be reassessed and potentially shift into different risk categories and experience changes 
in their management). Over the remainder of the model's lifetime horizon, the model continued to 
accrue health benefits in terms of QALYs and health system costs until the entire original cohort has 
either died of CVD, died from other causes, or has reached the age of 110 years. All QALYs and costs 
accrued in the model were discounted annually at 3%. The timeline of model events is summarised in 




Figure 3: Timeline of events over the lifetime model horizon 
 
4.3.8 Uncertainty and variation  
Modelling future outcomes inevitably involves uncertainty. Uncertainty in the model can arise due to 
population heterogeneity, stochastic uncertainty (or chance), as well as uncertainty concerned with 
the model and parameter inputs. Heterogeneity was considered in the model through the division of 
the model population into CVD risk strata which allowed for more specific differences in health and 
cost outcomes by CVD risk to be observed. Parameter and model input uncertainty was considered 
through applying uncertainty margins. Inputs that had uncertainty published in the literature (ie, the 
95%CI:of the clinical efficacy relative risks) were utilised if available. Remaining model inputs were 
assigned an uncertainty estimate of +/- 5% or 10% standard deviation of the mean, depending on the 
evaluated uncertainty of these variables (see Table 6 for baseline parameter uncertainty and  
Table 12 input parameter uncertainty). Each CVD risk stratum was simulated 2000 times in Microsoft 
Excel using an Ersatz add in to permit Monte Carlo simulations for all model variables with specified 
uncertainty. Monte Carlo simulation allows for the random selection of a value from the uncertainty 
range of all model inputs with assigned uncertainty. It aims to address both stochastic uncertainty 
(proportion of the population with the same characteristics has a different experience in the model 
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each time it is run due to chance) and model uncertainty (uncertainty around the central estimate). 
Despite these efforts to consider uncertainty in the model, it is possible that the true level of 
uncertainty is greater still (eg, no separate models were built to assess the role of model structure 
uncertainty).  
4.4 Intervention parameter selection  
4.4.1 Clinical efficacy of the FDC AA regimen 
Search method 
A search of the literature was conducted in April 2017 using the MeSH search terms amlodipine 
besylate/atorvastatin calcium AND Efficacy in PubMed. Search results were limited to those published 
in the English language and those conducted in human subjects. Nineteen studies were identified in 
the search and were downloaded to Endnote where abstracts were reviewed for relevance. Studies 
were excluded if they did not involve a FDC, were a review or expert opinion publication or had an 
irrelevant comparison group (ie, the comparison group is the same FDC taken at a different time of 
day). After exclusions, six studies were included in the review. Reference lists of included publications 
were examined to identify any further publications not identified in the original search. A further five 
studies were added to the search from examining reference lists, bring the total number of studies in 
the review to 11.  
Summary of included studies  
The 11 identified studies in the structured review included multiple different clinical trials. The 
CAPABLE study conducted in the United States was the subject of two publications (Ferdinand et al 
2009100 and Flack et al 2008101). The GEMINI study was conducted in 27 countries and was the subject 
of the publications by Erdine et al 200967 and Blank et al 2005.102 Five of the studies, Flack et al 2008,101 
Erdine et al 2009,67 Blank et al 2005,102 Hobbs et al 2009103 and Ferdinand et al 2009100 were no 
comparison titration-to-goal studies where participants at the discretion of their doctor could have 
their dosage titrated up or down to receive any of the available eight doses of the pharmaceutical in 
order to best target their high blood pressure and high cholesterol (amlodipine/atorvastatin: 5/10, 
10/10, 5/20, 10/20, 5/40, 10/40, 5/80, 10/80 mg). The remaining six studies104-109 focused on the lower 
doses of the pharmaceutical, primarily, 5/10 mg and 10/10 mg. Most of the studies investigated the 
use of the FDC AA as a primary prevention measure. Studies ranged in participant numbers from 117 
to 2245, spanned 14-52 weeks in duration and were set in a range of populations globally. All included 
studies except, Zeng et al,107 were in some way affiliated or sponsored by Pfizer Pharmaceuticals, the 
company who held the original patent for this FDC under the brand name Caduet.110 A summary of key 
characteristics of the included publications are available in Appendix Three.  
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The rationale for chosen model parameter input for the clinical efficacy of the FDC AA 
Of the identified studies, no single study appeared to stand out as superior to the others in terms of 
size and methodological quality. However, the studies by Flack et al 2008,101 Erdine et al 2009,67 Hobbs 
et al 2009103 and Blank et al 2005102 appeared to be relatively well-conducted non-comparison, 
titration-to-goal, clinical trials with comparable study designs (see Table 7). In order to produce the 
best value of clinical efficacy for the FDC AA for the model in this thesis, a meta-analysis of the four 
similar studies was conducted by the author. None of the studies were over a long enough period to 
observe a difference in CVD endpoints (rates of CHD and stroke). However, all papers published data 
on the change in SBP, DBP and LDL-C from baseline. The aim of the meta-analysis was therefore to 
determine the mean difference in SBP, DBP and LDL-C over the study period that could be attributed 
to the FDC AA. The determined mean difference in blood pressure and cholesterol was then applied 
to published standardised relative risk for stroke and CHD events published by Karmali et al 2016.111  
The meta-analysis was conducted using Cochrane Review Manager software (RevMan 5.3). Three 
separate random effect analyses were conducted to determine the mean differences in SBP, DBP and 
LDL-C respectively from baseline over the study period as a result of taking the FDC AA. Random effects 
analyses were used as each study was conducted in a different population. Each of the published 
studies published baseline blood pressure and cholesterol values and the mean change in the same 
variables over the study period. Final values for blood pressure and cholesterol levels at the end of the 
studies and the associated error were not published but were calculated from the baseline and change 
from baseline values. Hobbs et al103 did not publish any error measurements for baseline or change 
from baseline values for SBP, DBP, LDL-C. The author of this study was emailed to obtain this 
information and while contact was established, no relevant data was received prior to the completion 
of this thesis. Excluding this study based on the absence of error measurements seemed unreasonable, 
so a decision was made to average the error associated with the other three trials and apply this to the 
Hobbs et al 2009 study. Removing Hobbs et al (2009) from the meta-analysis did not affect the overall 
measure of effect significantly but including it increased participant numbers greatly. Figure 4, Figure 
5 and Figure 6 show the results of the three meta-analyses.   
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Table 7: Summary of studies used in the meta-analysis to determine the best parameter for FDC AA 
efficacy for use in the model 
Study 
author/reference: 






Study name GEMINI Study Gemini- AALA CAPABLE  JEWEL 1 JEWEL 2 






















Population Group  Men and women aged 18-80 years with hypertension and dyslipidaemia 
who qualified for treatment according to their respective local guidelines.  
Key inclusion/ 
exclusion criteria 
Exclude if blood pressure at goal (LDL-C could be at goal), already treated 
with amlodipine + atorvastatin monotherapy, taking any CCB or 
atorvastatin as monotherapy at maximum dose. History of CVD in 3 
months pre-screening. (Flack et al also excluded MI event in past six 
months). 
Study Design Open label, non-comparison, titration-to-goal. 
Eight doses amlodipine/atorvastatin - 5/10, 10/10, 5/20 10/20, 5/40, 
10/40, 5/80, 10/8 mg. 
Lifestyle change recommended to all participants 
Anti-hypertensive pharmaceutical other than CCB permitted, no other 
lipid-lowering pharmaceutical. No washout period.  
Baseline population 
(n) 
1220 1649 499 1138 1107 
Proportion of 
participants who 
completed the study 
89.8% 92.1% 74.9% 87.6% 87.8% 
Duration (weeks) 14 14 20 16 16 
 
The results of the meta-analyses demonstrated statistically significant reductions in SBP, DBP and LDL-
C as a result of treatment with the FDC AA over the study period. SBP changed by a mean of -18.92 
mmHg (95%CI: -21.31 to -16.57), DBP changed by a mean of -10.90 mmHg (95%CI: -11.89 to -9.92) and 
LDL-C changed by a mean of 1.04 mmol/L (95%CI: -1.17 to -0.91) from baseline over the average 16-
week study duration. Little variation was evident within the individual studies measure for SBP, DBP 
or LDL-C but there was considerable heterogeneity found in the meta-analyses (the high I2 results). The 
same studies in these meta-analyses were the subject of a pooled analysis by Feldman et al 2012.112 
Although this publication only states the results by age strata (no aggregate analysis presented), the 
values for change in blood pressure and cholesterol are relatively similar in magnitude to those 
calculated in the meta-analysis in this thesis. Relative risks for stroke, CHD and vascular events were 
then generated by applying the mean difference from baseline determined in the meta-analyses to 
standardised relative risks published by Karmali et al 2016.111 The resulting RR were then integrated to 
produce a RR reduction for CHD and stroke respectively. The 95% confidence intervals and standard 






























Figure 6: Random effects meta-analysis of change in LDL-C from baseline with FDC AA treatment. 
 41 
Table 8: Combined clinical efficacy of the FDC AA regimen in reducing the risk of CVD events (used 







results (see above) 





RR for stroke per 10/5 mmHg BP 
reduction 
0.54 (95%CI: 0.45 to 0.65) 





RR for CHD per 10/5 mmHg BP 
reduction 
0.79 (95%CI: 0.72 to 0.86) 





(change in LDL) 
RR per 1mmol/L reduction in LDL 
major vascular events 
0.75 (95%CI: 0.70 to 0.80) 
0.74 (SD 0.106)  
Combined RR for stroke events from taking the FDC AA regimen (A*C) 0.237 (SD 0.082) 
Combined RR for CHD events from taking the FDC AA regimen (A*B) 0.476 (SD 0.058) 
Abbreviations: RR (relative risk), 95%CI (95% confidence interval), SD (Standard deviation) 
Ersatz Excel plugin used to generate combined mean and 95%CI by running 2000 iterations of a 
log-normal distribution 
 
Excluded studies  
The remaining studies were not considered to inform the efficacy of FDC AA because they either 
studied a lower dose of FDC (5 mg/10 to 10/10 mg)105, 106, 108, 109 than the dose chosen to be modelled 
(see Section 4.4.2) or they examined a scenario that did not align with the intended modelling base-
case (ie, goal attainment by diabetes and metabolic syndrome status,100 best time of day to take 
pharmaceutical107). Neutel et al 2009104 was the only study that considered the same dose that was 
modelled in this thesis. However, the strength of evidence determined in the meta-analysis of the four 
titration-to-goal studies was considered a better source of evidence to inform the clinical efficacy of 
FDC AA than the Neutel et al 2009 study.  
FDC AA Adverse events  
Adverse events that lead to discontinuation of FDC AA appear to be relatively low. In the four studies 
considered in the above meta-analysis (Flack et al 2008,101 Erdine et al 2009,67  Hobbs et al 2009103 and 
Blank et al 2005102) adverse events ranged from 3.2% to 7.4% (over the 14 to 20 weeks duration of the 
studies). Adverse events were not directly included in the model directly. Rather it was assumed that 
discontinuation of the FDC due to adverse events would be partly captured in the adherence rate.  
4.4.2 Pharmaceutical dose 
It is important to note that clinical efficacy calculated in the meta-analysis above did not represent the 
clinical efficacy associated with a specific dose of the FDC AA, but rather the average clinical efficacy 
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across all available doses. However, because each available dose of FDC AA differs in cost, it was 
necessary to select a single dose that the pharmaceutical price could be based on. The FDC AA is 
currently available in eight doses with the amlodipine component being five mg or 10 mg and the 
atorvastatin component ranging from 10, 20, 40 or 80 mg.59, 61 It was decided that best way to 
determine the dose that would be modelled in this thesis would be to average the mean final dose of 
the same four titration-to-goal studies considered in the FDC AA clinical efficacy meta-analysis67, 101-103 
(ie, the doctor and/or pharmacist could modulate the dose of each component to best address the 
patient's risk profile). The average mean dose reached at the end of each of these four studies was 
calculated to be 7.3  mg of amlodipine and 24.6 mg of atorvastatin. This most closely matches with the 
possible dose, 5 mg of amlodipine and 20mg of atorvastatin, which was chosen as the dose to model 
in this study for both the FDC and the two agents taken separately (see Table 9).  





Blank (2005)102 7.1 26.2 
Flack (2008)101 8.2 26.4 
Erdine (2009)67 7.1 19.7 
Hobbs (2009)103 J1* 
                             J2* 
7.3 26.8 
6.7 24.1 
Average  7.3 24.6 
*JEWEL 1 (J1) and JEWEL 2 (J2) refer to two different 
populations within the same study  
 
4.4.3 Clinical efficacy of A+A  
Clinical efficacy of amlodipine monotherapy  
In the first instance, the Cochrane Library was searched for any reviews concerning the efficacy of 
amlodipine compared to placebo or usual care. No appropriate reviews were found. Subsequently, a 
structured review was carried out using the following MeSH search terms in PubMed: Meta-analysis 
AND amlodipine AND hypertension AND cardiovascular disease. The same search strategy and 
protocol used in the FDC AA clinical efficacy search was employed here. The search identified 16 
studies. None of the identified studies were considered appropriate to inform the model input of 
amlodipine clinical efficacy. Most of these studies were concerned with combination therapy, 
compared amlodipine directly to other anti-hypertensives, focused on stroke or CHD not both and 
were conducted in specific populations (ie, people with diabetes).  
Two subsequent searches were conducted with the aim of determining the clinical efficacy of CCBs or 
anti-hypertensives more broadly. The following searches were conducted in PubMed in July 2017. 
Search 1: "Blood Pressure"[MeSH]) AND "Meta-Analysis" [Publication Type] AND "Calcium Channel 
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Blockers"[MeSH]. Search 2: "Blood Pressure"[MeSH]) AND "Anti-hypertensive Agents"[MeSH] AND 
"Meta-Analysis" [Publication Type]. The same search strategy described above to refine the research 
results was used here. Search One returned 31 publications and after exclusions, three studies 
remained. Search Two returned 192 publications, 19 of which were deemed relevant upon scoping. Six 
publications were read in full. The three relevant studies identified in Search One also appeared in 
Search Two. A summary of the included studies can be found in Appendix Four.  
Overall the meta-analysis conducted by Thomopoulos et al 2015113 was considered the best study to 
inform the parameter of amlodipine efficacy. The study was the most recent review of the six studies 
considered and looked at the primary prevention impact of each anti-hypertensive class on CVD risk 
compared to placebo or usual care. In total, the meta-analysis considered 55 studies and 
approximately 200,000 people and appeared to be well-conducted. The CCB analysis within the meta-
analysis (10 RCTs, approximately 30,000 people) included a sensitivity analysis of four studies which 
were conducted in entirely hypertensive cohorts who were taking no or minimal baseline 
pharmaceuticals. This sensitivity analysis is of value as it aligns with the aim of this thesis, which is 
focused on a primary prevention intervention. See Table 10 for the relative risks used.  
Another review by Law et al in 2009,114 received strong consideration to inform this input parameter 
as it was also a large-scale, well-conducted meta-analysis that considers the efficacy of anti-
hypertensive on the risk of CVD by pharmaceutical class. However, this review included fewer studies 
overall, partly due to an earlier publication date (CCB analysis similar) and did not distinguish between 
studies that considered hypertensive or normotensive cohorts, or those considering the 
pharmaceuticals for primary or secondary care. Briasoulis et al 2014115 was not considered as it looked 
at the effect of anti-hypertensives on a population of people aged 65 or older and none of the other 
data inputs were age-specific. The other remaining publications116-118 were not utilised as they 
considered comparisons not relevant to this input parameter or where inferior in quality of evidence 
to Thomopoulos et al 2015.113  
Amlodipine adverse events  
Amlodipine, in general, appears to be a well tolerate pharmaceutical with a low risk of adverse events. 
Notably, the adverse event rate with amlodipine does not vary significantly from the adverse event 
rate of other first-line hypertension pharmaceuticals.119 
Clinical efficacy of atorvastatin monotherapy  
Before a structured search of the literature was conducted, the Cochrane Library was first searched to 
see if any reviews were conducted concerning the clinical efficacy of atorvastatin. One review 
conducted by Adams et al in 2015120 was identified which aimed to determine the mean percentage 
change from baseline of LDL-C with atorvastatin among those with or without CVD. The review collated 
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296 studies involving 38,817 participants and compared atorvastatin to baseline or placebo. The 
Cochrane Library reviews are considered the gold standard of meta-analyses and systematic reviews. 
Given this reputation, the large number of included studies and participants, in addition to the high 
quality of included studies (determined by Cochrane), this study was chosen to inform the clinical 
efficacy of atorvastatin in this model. The study duration did not allow for changes in CVD event rates 
to be observed. As per the clinical efficacy parameter of the FDC AA, the mean difference in LDL-C from 
baseline for 20 mg of atorvastatin (1.09 mmol/L) was applied to the standardised RR for major vascular 
events 1 mmol/L reduction in LDL-C as reported by Karmali et al 2016.111 Major vascular events include 
fatal and non-fatal CHD and stroke. See Table 10 for final relative risk.  
Atrovastatin adverse events  
The same Cochrane Review by Adams et al 2015120 reported that there was no statistically significant 
difference in the rate at which people withdrew from the study due to the adverse effects of all doses 
of atorvastatin (odds ratio 0.98 (95%CI: 0.68 to 1.40)). A total of 34 studies were included in this 
analysis and the Cochrane Review determined that the quality of evidence of this measure was very 
low. The measure does not appear to separate withdrawals due to study pharmaceutical related 
adverse events or general adverse events. Adverse events were not directly considered in this model 
as it was assumed they would be reflected in the pharmaceuticals adherence rates. Including 
adherence rates may have resulted in some double counting.  
Combined clinical efficacy for A+A  
The relative risk for the clinical effect of amlodipine and atorvastatin on stroke, CHD and vascular 
events respectively where combined to give an overall relative risk that represents the clinical efficacy 
of those taking amlodipine and atorvastatin as two separate pills for stroke and CHD respectively (see 
Table 10 for more detail).   
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Table 10: Combined clinical efficacy of amlodipine and atorvastatin as two separate pills for CVD 
event reduction (for parameter input into the model) 









et al 2015113 
RR for CCB vs usual 
care/placebo includes fatal 
and non-fatal stroke 
events.  
Relative risk = 0.63  







et al 2015113 
RR for CCB vs usual 
care/placebo includes fatal 
and non-fatal CHD events 
Relative risk = 0.74  









Adams et al 
2015120 + 
Karmali et al 
2016111 
Mean change LDL-C from 
baseline 20 mg atorvastatin 
from Adams et al 2015 
(1.09 mmol/L) applied to 
standardised relative risk 
per 1 mmol/L reductions in 
LDL-C from Karmali et al 
2016 (RR 0.74 95%CI: 0.66 
to 0.81). Measure 
aggregates fatal and non-
fatal stroke and CHD 
Relative Risk = 0.73  
(95%CI: 0.68 to 
0.78)  
Combined RR for stroke events from taking the A+A regimen [A*C] 0.460 (SD 0.023) 
Combined RR for CHD events from taking the A+A regimen [B*C] 0.540 (SD 0.028) 
Abbreviations: RR (relative risk), 95%CI (95% confidence interval), SD (Standard deviation)  
Ersatz Excel plugin used to generate combined mean and 95%CI by running 2000 iterations of a 
log-normal distribution 
4.4.4 Adherence  
Method  
A structured search of the literature was conducted in April 2017 using the search terms amlodipine 
besylate/atorvastatin calcium AND adherence in PubMed. The process of restriction, review and 
evaluation was repeated as previously detailed. Of the 19 studies originally identified in the search, 
five studies were included in the final review. After examining the reference lists of the included 
publications, one further publication was added bringing the total number of studies included in the 
review to six.  
Summary of identified studies  
Of the six included studies, five were conducted using a retrospective cohort study design, four of these 
studies looked at administrative claim data of insurance enrollees in the United States and one looked 
at prescription claims data in Australia. The only study not retrospective in nature was by Zeng et al 
2016107 who utilised a case-control study design. Four of the six identified studies were in some way 
affiliated or sponsored by Pfizer Pharmaceuticals. A summary of the publications is available in 
Appendix Five. 
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Rationale for selecting the best study for informing the adherence parameter 
Of the identified studies, probably the best study to inform the adherence input parameter for 
modelling purposes is that by Patel et al 2008.68 Although this study is the oldest publication identified 
in this literature review, it appears to provide the strongest evidence available regarding the adherence 
of the FDC AA. The study compares the adherence of the FDC AA with amlodipine and atorvastatin 
taken as two separate pills in a population of 4,703 United States nationals (one-year analysis n=3561), 
which is the precise comparison that was aimed for in this New Zealand modelling work. The study 
looked at adherence using pill days covered over a six month and 12 month time horizon. The study 
population of United States nationals is probably of reasonable generalisability to New Zealand as the 
United States is another high-income English-speaking country. The adherence results of this study 
were of a similar magnitude to those in the other studies identified in the search. Furthermore, most 
of the cost-effectiveness studies identified in the literature review Section of this thesis (Section 3.2) 
base adherence on the data from the Patel et al study.68, 75, 76  
Patel et al68 found that after one year 63.9% of people taking the FDC AA regimen were adherent 
(greater than 80% pill days covered (PDC)) compared to 33.1% to 43.6% for those taking two separate 
pills (amlodipine and atorvastatin, amlodipine and a statin, CCB and atorvastatin or CCB +statin). As a 
value, specifically for amlodipine and atorvastatin adherence as separate pills at one-year was not 
published in this paper, the average of the adherence range at one-year for the two separate pills was 
calculated to inform the adherence parameter of the A+A regimen (38.4%). Ideally, adherence in the 
model would begin at 100%, decrease in the first year to the values outlined in Patel et al68 and then 
remain constant over the remainder of the five-year intervention period. Due to characteristics of the 
existing model and the time constraints of this thesis, changing the model to represent adherence in 
this way was not considered possible. Consequently, adherence values were assumed to begin at 100% 
and decrease to 63.9% and 38.4% respectively over the five-year intervention period (an annual 
decrease of 7.2% for FDC AA and 12.3% for A+A). The implications of representing adherence in this 
way are discussed in the Discussion, Section 6.5.3.  
The study conducted in Australia by Simons et al in 201169 received strong consideration for use in the 
New Zealand modelling work. Studies conducted in Australia are generally considered to have 
reasonable generalisability to the New Zealand population (at least for the New Zealand European 
population). The study included a large study population and unlike Patel et al68 it was conducted 
independently to Pfizer. However, one major limitation of this study is that the cost of amlodipine at 
all doses is less than the general co-payment threshold, which is not recorded by Medicare. Therefore, 
the data on amlodipine monotherapy is only representative of concessional patients (patients who 
have a health card to receive discounted medical care and prescriptions due to low-income or being a 
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high-users) which the study estimates represent 65% of amlodipine users. This potentially introduces 
a selection bias if those that were included in the monotherapy arm of this study were different in 
some way from those in the single-pill arm of this study. With such a high proportion not being 
represented in this study, it was considered unwise to use this study to inform an input parameter.69 
Notably, however, the confidence limits of the study by Simons et al 69 is contained within the 95%CI 
for adherence from Patel et al.68 
The following paragraph outlines the reason why the remaining articles were not chosen to inform 
adherence in the model. The study conducted by Zeng et al 2016107 had the primary focus of 
investigating whether the time of day the pharmaceutical was taken affects the clinical efficacy. 
Compliance with the FDC AA was a secondary aim and no measure of association was measured in this 
study resulting in an inferior study result than the other studies. The two studies conducted by 
Chapman et al in 2009121 and 201070 used unspecified CCBs or statins in their comparison group. This 
is an issue for two reasons: 1) it does not match the primary comparison this thesis intended on 
modelling (ie, a FDC AA compared to amlodipine and atorvastatin taken as individual pills; 2) it would 
be more difficult to determine the effectiveness parameters. Finally, the study conducted by Hussein 
et al in 2010122 focuses on the effect of previous statin and CCB use on the odds of adherence. While 
this is a useful and interesting study, it goes beyond the aims of this thesis and the capacity of the CVD 
model.  
4.4.5 Intervention cost  
As the model used in this thesis used a health system perspective, the intervention costs considered 
were the cost to the government to provide the FDC AA or A+A (pharmaceutical cost) and the out-of-
pocket co-payment costs for the patient (prescription cost). 
Pharmaceutical cost  
The FDC AA is not currently available in New Zealand.66 As a result, the likely price of such a 
pharmaceutical on the New Zealand market is unknown. Initially, price scaling between 
pharmaceuticals in Australia was considered as the best method to estimate the cost of the FDC AA in 
New Zealand as a mean percentage difference in price between Australia and New Zealand 
pharmaceuticals could be applied to the known price of FDC AA in Australia. However, it became 
apparent that Australia has unique regulations around FDCs.123 For most of the FDCs approved in 
Australia, it is conditional that they remain cheaper than their monotherapy components. 
Furthermore, the price of the FDC is linked to the cost of their components meaning any price 
decreases applied to the components are translated to the price of the FDC. However, if a second 
brand of the FDC is introduced, the link between the FDC and its components no longer applies and 
the FDC is ultimately subject to market forces. Competition for FDCs is not as significant as it is for most 
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monotherapies, so the price of FDCs generally ends up being more expensive than their monotherapy 
components.123 Because of these unique regulations and the large potential variation in the cost of 
FDCs in Australia, using price scaling to determine the cost of FDC AA in New Zealand would have 
generated a price estimate with little applicability to New Zealand. The FDC is also currently approved 
in some European countries and the United States but the funding of pharmaceuticals in these 
countries differs significantly to New Zealand and consequently were considered not to provide a 
reasonable comparison for price scaling.  
Given the above, an alternative method, which estimated the price of the FDC AA based on the price 
of amlodipine and atorvastatin monotherapy was used. Basing the price on current monotherapies is 
often used in polypill research where the price is also often unknown.83, 85 As published on the 2017 
PHARMAC pharmaceutical schedule, five mg of amlodipine monotherapy costs the New Zealand 
Government $0.01 per pill and 20 mg of atorvastatin $0.03 per pill (both in 2011 NZ$). Thus, an 
individual in the comparison group of this analysis who was prescribed both amlodipine and 
atorvastatin would have a total cost to the New Zealand Government of $0.04. The base case of the 
FDC intervention, therefore, assumed the FDC costs to be the same as the same two agents as 
monotherapy. This, therefore, meant that the health cost differences between the two regimens 
became the marginal difference in prescription costs (two for monotherapy, one for the FDC) and the 
differences in health costs (via the differences in clinical efficacy and relative adherence of the two 
regimens).  
Prescription costs 
Amlodipine and atorvastatin are both listed in the 2017 Pharmaceutical Schedule as potentially three-
month prescriptions, meaning that three months or 90 days of the pharmaceutical can be dispensed 
at the same time.66 As a result, an individual who is taking the pharmaceutical as prescribed would be 
expected to require four repeat prescriptions a year. In 2017, the total cost per prescription for a fully 
subsidised pharmaceutical (like amlodipine or atorvastatin) was $5.44 exclusive of GST (with this 
amount changing slightly in most years). This cost includes the cost to the pharmacy to procure, store 
and dispense the pharmaceutical.124-126 After adjustment using the international consumer price index 
(CPI) published by Organisation for Economic Co-operation and Development (OECD),127 the 
prescription cost in 2011 New Zealand dollars (model baseline) was calculated to be $5.21. At this cost, 
an individual taking both amlodipine and atorvastatin as two separate pills as prescribed over a 12-
month period would have a prescription cost of $41.68 exclusive of GST (($5.21 x 4 prescriptions 
annually) x 2 pharmaceuticals). If the same conditions were to apply to the FDC AA if it was available 
in New Zealand (as per the assumptions used, ie, fully subsidised and available as 90-day prescriptions) 
the annual prescription cost of a single fully subsidised pharmaceutical would be $20.84 excluding GST 
($5.21 x 4 prescriptions annually) (Table 11).  
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The calculated prescription cost of the FDC AA assumes that a patient was prescribed the FDC AA 
during a routine GP appointment that would have occurred regardless since the patients in the 
comparison group in this model are already taking the amlodipine and atorvastatin as separate pills 
(ie, the patient would have to go to the doctor to collect a repeat prescription four times a year 
regardless of the regimen). Therefore, there is no difference in annual GP visits and associated costs 
between the two groups. Additionally, it is assumed that once the switch to FDC AA has occurred, no 
additional GP appointments are required due to issues specifically related to the FDC AA.  
Table 11: Pharmaceutical costs per 90-day prescription period, per year and intervention period (all 







Total cost (Pharmaceutical + 
Prescription cost) 
Pharmaceutical 
cost per pill 
(price/pill) 
Prescription 














Amlodipine single pill 
(5 mg)66 
$0.01 $5.21 $6.11 $24.78 $123.90 
Atorvastatin single 
pill (20 mg)66 
$0.03 $5.21 $7.91 $32.08 $160.40 
Amlodipine (5 mg) + 
Atorvastatin (20 mg) 
$0.04 $10.42 $14.02 $56.85 $284.29 
FDC AA (5 mg/20 mg) $0.04 $5.21 $8.81 $35.73 $178.65 
All prices are in 2011 NZ. * = (cost per 90 day prescription period/90) x number of days) 
4.4.6 Intervention uptake  
Intervention uptake or the proportion of the model population who received either intervention (be 
prescribed either FDC AA or A+A) was also estimated. This was informed by recent modelling work by 
Knight et al 2017,93, 94 which was also used to inform the stratification of the population into CVD risk 
strata. Based on the figures by Knight et al93, 94 on the proportion of people in the model population 
who were on either an anti-hypertensive, a statin, or both, 46% of Māori men and 38% of non-Māori 
men within each risk stratum were assumed to receive either intervention.  
4.4.7 Summary of intervention parameters  
Table 12 summarises all the intervention input parameters for both FDC AA and A+A, their source and 
their uncertainty.  
4.4.8 Scenario and sensitivity analyses 
Several sensitivity and scenario analyses that varied intervention input parameters were carried out. 
The rationale and detail of each analysis is outlined in Table 13  
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Table 12: Summary of intervention inputs FDC AA and A+A  
Input Parameter Source Value Uncertainty  
FDC AA – 5 mg Amlodipine/20 mg Atorvastatin 
Clinical Efficacy  
 
Random effects meta-analysis of change in SBP and LDL-C from baseline from Blank et al 
2005,102 Flack et al 2008,101 Erdine et al 200967 and Hobbs et al 2009.103 (Figure 4, Figure 5 and 
Figure 6). The resulting change in SBP and LDL-C applied to standardised RR for CVD events 
published in Karmali et al 2016111. Ersatz Excel plugin used to generate combined mean and 
95%CI by running 2000 iterations of a log-normal distribution (Table 8).  
Relative Risk  Stroke 0.237 (SD 
0.082), CHD 0.476 
(SD 0.058) 
Adherence Adherence declined uniformly over the five-year intervention period from 100% at baseline to 
63.9% for the FDC AA (annual decrease of 7.2%)68 






FDC AA 2011NZ$0.04 per pill (estimated), prescription cost 2011NZ$5.21 – Price scaling from 
90-day prescription period to estimate five-year cost (Table 11).  
2011 NZ$178.65 
 
SD  10% of the 
point estimate 
gamma distribution 
A+A – 5 mg Amlodipine + 20 mg Atorvastatin 
Clinical Efficacy  Change in LDL-C from Adams et al 2015120 (Atorvastatin) applied to standardised RR from 
Karmali et al 2016.111 RR for Amlodipine from Thomopoulos et al 2015113 (Amlodipine). 
Multiplication of RR for stroke, CHD and vascular events. Ersatz Excel plugin used to generate 
combined mean and 95%CI by running 2000 iterations of a log-normal distribution (Table 10). 
Relative Risk 
 
Stroke 0.460 (SD 
0.023). CHD 0.540 
(SD 0.028) 
Adherence Adherence declined uniformly over the five-year intervention period from 100% at baseline to 
38.4% for A+A (an annual decrease of 12.3%).68 






A+A 2011NZ$0.04 per pill (PHARMAC) two x prescription cost 2011NZ$10.42 – Price scaling 
from 90-day prescription period to estimate five-year cost66 
2011 NZ$284.29  
 
SD  10% of the 
point estimate 
gamma distribution 
Parameters common to FDC AA and A+A  
Intervention Uptake Modelling work by Knight et al 201793, 94 in a synthetic New Zealand population estimated that 
46% of Māori and 38% of non-Māori of NZ men aged 60 to 64 were currently either on an anti-
hypertensive, a statin or both.  
46% of Māori and 38% 
of non-Māori within 
each risk stratum 





To approximate five-year absolute risk reduction after which it is assumed that the absolute risk 
level would be reassessed by the GP. 
Five years n/a 
Abbreviations: RR (relative risk), SBP (systolic blood pressure), LDL-C (low-density lipoprotein cholesterol), SD (standard deviation), 95%CI (95% confidence interval)  
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Table 13: Description of scenario and sensitivity analyses 
Model input sensitivity analysis  
Cost of FDC AA In the base-case, the cost of FDC AA was $0.04 per pill. Two sensitivity analysis were done which considered a price 
of $0.02 and $0.08 per pill.  
Discount rate The discount rate for both QALYs and costs was varied to 0% and 6% annually (relative to 3% in the base-case).  
Intervention parameter scenario analysis.  
Equity analysis  Māori experience an inequitable burden of CVD. This scenario analysis explored the impact on results if Māori had 
the same capacity to benefit from treatment (same background-mortality and morbidity rate) as non-Māori.  
Worse-case uptake and adherence  The lower values of the 95% confidence interval for both adherence and uptake for both the FDC AA and A+A 
regimen were used in the model rather than the mean.  
Ethnic group variation in adherence  Adherence to pharmaceuticals among Māori has sometimes been reported to be lower than non-Māori. A sensitivity 
analysis was considered were adherence rates of Māori were 11% lower than that of non-Māori.128 
Equal Efficacy  FDC are generally required to be at least equal in efficacy to their monotherapy components. In this sensitivity 
analysis, the clinical efficacy (relative risk, RR) for the FDC AA was reduced to be equal to the clinical efficacy of A+A. 
The primary difference between the use of the FDC AA and A+A becomes a function of the difference in adherence 
and the prescription cost.  
Uptake at the start of modelling for both 
regimens to 80% 
The proportion of the study population prescribed either pharmaceutical at baseline was increased to 80% for both 
Māori and non-Māori to explore the magnitude of potential health gain that could be expected if more people than 
currently, take preventive CVD pharmaceutical, in particular, FDC. 
Time Horizon  The QALYs gained and the cost-offsets over five-year, 10-year and 20-year time horizon were considered (relative to 
a lifetime horizon in the base-case).  
 52 
Chapter 5: Results  
This Chapter describes the results generated by the BODE3 CVD MSLT model if New Zealand men aged 
60 to 64 years, who were free of CVD and assumed to be taking A+A, switched to the FDC AA. The 
Chapter begins by describing the results from the base-case analysis overall and by five-year absolute 
CVD risk (Section 5.1). Section 5.2 compares the results of two sensitivity analyses with the base-case 
results and Section 5.3 describes the results of the various scenario analyses. The Chapter concludes 
by considering the impact of all sensitivity analyses on the base-case results and overall cost-
effectiveness (Section 5.4).  
5.1 Base-case results 
5.1.1 Overview  
The base-case analysis examined the difference in the QALYs gained and health system costs if a 
population of New Zealand men aged 60 to 64 with no history of CVD and assumed to be taking A+A 
as two separate pills, were offered to switch to the FDC AA. Intervention uptake for both 
pharmaceutical regimens was 46% for Māori and 38% for non-Māori within each risk stratum (the best 
estimate for the proportion of men in this age group taking both an anti-hypertensive and a lipid-
lowering pharmaceutical and therefore eligible to switch to the FDC AA). Adherence was assumed to 
decline uniformly over the five-year intervention period from 100% at baseline to 63.9% for the FDC 
AA (an absolute decrease of 7.2 percentage points per year) and to 38.4% for A+A (an absolute 
decrease of 12.3 percentage points per year). Health gains (QALYs) and costs were accrued over a 
lifetime horizon and were discounted at 3% annually. Table 14 shows the incremental QALYs gained, 
the cost-offsets (net cost-savings) and the incremental cost-effectiveness ratio (ICER) by CVD risk strata 
if this cohort of men switched from A+A to use the FDC AA under the conditions of the base-case. 
Figure 7 and Figure 8 illustrate the QALYs gained and the cost-offsets (savings) on a cost-effectiveness 
plane.  
5.1.2 Risk strata combined  
Overall, under the conditions of the base-case, switching from A+A to the FDC AA was cost-saving (95% 
uncertainty interval (95%UI): cost-saving to $3,570 per QALY gained) (Table 14). That is, switching to 
use the FDC AA for five-years resulted in additional health benefit and greater cost-offsets (savings) 
over a lifetime time horizon than the use of A+A under the same conditions. Overall, switching to use 
the FDC AA resulted in an additional 86.2 QALYS (95%UI: 0.00 to 386) gained in this age-cohort of men 
and an additional -$1.24 million dollars (95%UI: -$6.10 million to $0.028 million) in cost-savings 
compared to the use of A+A (discounted at 3% annually). 
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5.1.3 Results by risk stratum 
Within each of the five CVD risk strata, the use of the FDC AA resulted in additional QALY gains and 
additional cost-offsets (savings) than the use of A+A (albeit not significant – ie, there was a small 
chance of a positive cost). The ICER in favour of the FDC AA in risk stratum one (lowest CVD risk) ranged 
from cost saving to $2.12 per QALY gained (or 472,000 QALYs per million dollars spent) at the upper 
bound of the 95%UI. The use of FDC AA in risk stratum four and five (highest CVD risk) ranged from 
cost-saving to $3,940 per QALY (or 253 QALY per million dollars spent) and $3,570 per QALY gained (or 
280 QALYs per million dollars spent) respectively, compared to the use of A+A. (see Table 14,  Figure 7 
and Figure 8) 
The total QALYs gained were greatest in risk stratum one and two (since these strata had the largest 
numbers of simulated individuals) and decreased as CVD risk increased. The QALYs gained per 1,000 
people who took either pharmaceutical regimen at baseline in each CVD risk stratum (per capita) 
shows the opposite pattern in QALYs gained. That is, the per capita QALY gains were greatest in the 
highest CVD risk strata and decreased as CVD risk decreased. The largest per capita health gain was 
observed in risk stratum five with 78.1 QALYs per 1,000 people who received medication. The smallest 
per capita health gain was observed in risk stratum one with 11.4 QALYs per 1,000 people. The absolute 
QALYs gained were larger for non-Māori than Māori. However, the per capita QALY gains, which 
remove the influence of differing population numbers between Māori and non-Māori, showed the 
QALYs gained by Māori in risk stratum one and two were similar between Māori and non-Māori. Across 
risk stratum four to five the additional QALYs gained per capita were slightly larger for non-Māori than 
Māori. The cost-offsets (savings) illustrate a similar pattern to the QALYs gained with the greatest 
absolute cost-offsets being observed in risk stratum one and two, decreasing in magnitude as CVD risk 
increases. None of the absolute cost-offsets (savings) were significant (ie, there was a chance the cost 
could be positive) . The cost-offset per capita did not differ considerably by risk strata.  
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Table 14: The additional health gain (QALYs), the additional cost-offsets (savings) and the 
incremental cost-effectiveness ratio if the estimated 38% non-Māori and 46% of Māori 
men aged 60 to 64 years in 2011 who were assumed to be on A+A switched to the FDC 



























Risk Stratum 5:  
>20%  
(n= 19; 22) 
1.93 
(1.17 to 5.05) 
1.30 
(0.97 to 3.77) 
3.23 
(1.42 to 7.80) 
$-0.009 




Risk Stratum 4:  
>15%, 20%  
(n= 73; 104) 
6.79 
(3.80 to 17.8) 
3.83 
(2.96 to 10.9) 
10.6 
(4.40 to 26.1) 
$-0.049 ( 




Risk Stratum 3:  
>10%, 15% 
(n= 333; 738) 
32.2 
(14.2 to 80.0) 
12.6 
(8.04 to 34.4) 
44.7 
(15.6 to 105) 
$-0.324 




Risk Stratum 2:  
>5%, 10 
(n= 1125; 7674) 
168 
(84.1 to 429) 
24.8 
(13.6 to 67.6) 
193 
(81.5 to 474) 
$-2.53 




Risk Stratum 1:  
>0%, 5%  
(n= 377; 14,236) 
163 
(74.1 to 404) 
4.72 
(2.61 to 12.3) 
167 
(73.0 to 412) 
$-3.41 









(0 to 636) 
9.89 
(0 to 49.2) 
86.2 
(0 to 386) 
$-1.24 




B. QALYs / 1,000 people & $ per person who received either pharmaceutical regimen at the start of the 
model (uptake)  
Risk Stratum 5 87.6 68.8 78.1 -$221 – 
Risk Stratum 4 67.2 52.5 59.5 -$275 – 
Risk Stratum 3 43.7 37.9 41.5 -$301 – 
Risk Stratum 2 21.9 22.0 21.9 -$287 – 
Risk Stratum 1 11.4 12.5 11.4 -$233 – 
Range represents the 95% uncertainty interval (95%UI) of 2000 Monte Carlo simulations per risk stratum  
Note: approximately 8% of the 2000 Monte Carlo simulations were excluded from calculations due to the occurrence 
of negative QALYs. Negative QALYs occurred due to the two pharmaceutical regimens being modelled sequentially and 
subtracting the respective outputs. Had the regimens been modelled in parallel, negative QALYs would not have been 
possible (see Section 6.5.2 of this thesis for further detail).  
QALYs (quality-adjusted life-years): ICER (incremental cost-effectiveness ratio) 





Figure 7: Cost-effectiveness plane showing the incremental cost-offset and QALYs gained if the 
proportion of New Zealand men aged 60 to 64 who were assumed to be taking A+A 
switched to the FDC AA by five-year absolute cardiovascular disease risk strata (risk 
stratum one and five only)– Results of 2000 Monte Carlo simulations per CVD risk 
stratum. (Base-case conditions, five-year intervention period, lifetime horizon, 3% 
annual discount rate, outliers excluded*) 
* Approximately 8% of the 2000 Monte Carlo simulations were excluded from calculations due to the occurrence 
of negative QALYs. Negative QALYs occurred due to the two pharmaceutical regimens being modelled 
sequentially and subtracting the respective outputs. Had the regimens been modelled in parallel, negative QALYs 



































Risk strata one Risk strata five
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Figure 8: Cost-effectiveness plane showing the base-case mean values (with no uncertainty) for the 
incremental cost-offsets and QALYs gained by each risk stratum (RS) if the proportion 
of New Zealand men aged 60 to 64 who were assumed to be taking A+A switched to 
the FDC AA  
5.2 Sensitivity analyses  
Two sensitivity analyses were run in which the model discount rate (base-case 3%, sensitivity analysis 
0% and 6%) and cost of the FDC AA (base-case $0.04 per pill, sensitivity analysis $0.02 and $0.08 per 
pill) were varied. The details of each sensitivity analysis have been summarised previously in Table 13.  
Table 15 displays the expected values for the additional QALYs gained and cost-offset (savings) if a 
population of New Zealand men aged 60 to 64 assumed to be on A+A, switched to FDC AA under the 
conditions of each sensitivity analysis. As in the base-case, across all model sensitivity analyses, the 
absolute QALY gained and cost-offsets (savings) were greatest in risk stratum one and two and 
decreased as CVD risk increased. Furthermore, the observed pattern that the QALYs gained per capita 
were greatest among those with the greatest CVD risk, was also apparent here. Except for risk stratum 
five in the 0% discount rate scenario, switching from A+A to the FDC AA remained cost-saving. The 
ICER in risk stratum five with a 0% discount rate was $1,400 per QALY (716 QALYs per million dollars 
spent).  
Using a discount rate of 6%, (ie, the QALY gains and cost-offsets (savings) in the future are valued less 
than QALY gains and cost-offsets today) the number of QALYs gained decreased by approximately 32% 
while the cost-offsets increased. When a 0% discount rate was used (ie, the QALY gains and cost-offsets 
were of equal value in the future as QALY gains and cost-offsets today) the number of QALYS gained 



























change in QALYs from the base-case was least in risk stratum five and increased as CVD risk increased, 
while the percentage change in costs was greatest in risk stratum five and decreased as CVD risk 
increased. Changing the price of FDC AA to be half or double the cost used in the base-case did not 
affect the QALYs gained as expected and had only a small influence on the magnitude of cost-offsets 
(savings) from the base-case. Changing the price of the FDC to be half the cost used in the base-case 
increased the cost-offsets (savings) by approximately 11% on average. Doubling the price of the FDC 
on the other hand, resulted in a decrease of approximately 23% in the cost-offsets (savings) in each 
risk strata on average.  
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Table 15: The additional health gain (QALYs) and the cost-offsets if New Zealand men aged 60 to 64 years in 2011 who were assumed to be on A+A switched to 
the FDC AA – ethnic groupings combined, sensitivity analyses (0% and 6% discount rate, FDC AA cost 50% and 200%) 
Five-year absolute CVD risk 
strata 




























Risk Stratum 5: >20% 3.42 -$0.009 4.96 $0.007 2.45 -$0.017 3.42 -$0.01 3.42 -$0.01 
Risk Stratum 4: >15%, 20% 10.7 -$0.050 15.9 -$0.003 7.47 -$0.072 10.7 -$0.06 10.7 -$0.04 
Risk Stratum 3: >10%, 15% 44.6 -$0.326 68.5 -$0.149 30.4 -$0.396 44.6 -$0.360 44.6 -$0.26 
Risk Stratum 2: >5%, 10 197 -$2.51 316 -$1.98 130 -$2.62 197 -$2.79 197 -$1.96 
Risk Stratum 1: 0, 5 167 -$3.41 277 -$3.27 107 -$3.26 167 -$3.87 167 -$2.49 
B. QALYs / 1,000 people & $ per person who received either pharmaceutical regimen at the start of the model (uptake)  
Risk Stratum 5 (n=41) 83.0 -$221 120 $167 59.2 -$420 82.7 -$251 82.7 -$161 
Risk Stratum 4 (n=178) 60.0 -$281 89.0 -$15.7 41.9 -$404 59.8 -$311 59.8 -$220 
Risk Stratum 3 (n=1,078) 41.4 -$303 63.5 -$138 28.2 -$368 41.4 -$334 41.4 -$241 
Risk Stratum 2 (n=8,824) 22.3 -$285 35.9 -$224 14.7 -$296 22.3 -$316 22.3 -$223 
Risk Stratum 1 (n=14,631) 11.4 -$233 19.0 -$224 7.34 -$223 11.4 -$264 11.4 -$170 
*Base-case: 38% of non-Māori and 46% of Māori men aged 60 to 64 assumed to be on A+A switch to FDC AA, five-year intervention period, lifetime time horizon and 3% 
annual discount rate 
** The discount rate of all accrued QALYs and costs discounted varied from the base-case 3% to 0% and 6%. All other conditions as per the base-case 
 FDC AA cost 50% and 200%: The cost of the FDC AA was changed to be 50% and 200% of the base-case cost respectively. All other conditions as per the base-case. 
 n=46% of Māori and 38% of non-Māori in each CVD risk stratum  
All values are expected values. All figures are rounded to three meaningful digits. 
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5.3 Scenario analyses  
In addition to the discount rate and cost of the FDC sensitivity analyses, a range of scenario analysis in 
which various model or intervention parameters were varied, was done in order to observe the effects 
of several different plausible scenarios. The considered scenarios include: an equity analysis, worse-
case uptake adherence and uptake, ethnic group variation in adherence, equal efficacy of medication 
regimens, 80% uptake and three different time horizons. Each scenario analysis is summarised in Table 
13. Table 17 and Table 18 shows the additional QALYs gained and the cost-offsets (savings) for each 
scenario. Each scenario analysis will be discussed in turn below.  
The three notable patterns that were observed in the base-case analysis were preserved in all six 
scenario analyses. Firstly, in each analysis, the absolute QALYs gained and the cost-offsets (savings) 
attributed to switching to the FDC AA from A+A were greatest in risk stratum one and two and 
decreased as five-year CVD risk increased. Secondly, the additional QALYs gained from switching to the 
FDC AA adjusted by the number of people who received either pharmaceutical intervention at baseline 
was greatest in risk stratum five, the stratum with the greatest CVD risk and decreased as CVD risk 
decreased. This indicates that those with the greatest CVD risk also benefited the most from switching 
from A+A to the FDC AA. The cost-offsets (savings) per medicated person did not appear to differ 
substantially by CVD risk strata. Thirdly, switching to the FDC AA from A+A was cost-saving in each CVD 
risk stratum regardless of the scenario analysis.  
5.3.1 Equity analysis  
In New Zealand, Māori experience a greater burden of background mortality and morbidity than non-
Māori. To avoid the penalising effect of this inequity, an “equity analysis” was run in which non-Māori 
mortality rates and disability weights were applied to Māori. Essentially, this results in Māori having 
the same capacity to benefit from treatment with the FDC AA or A+A as non-Māori. Table 16 shows 
the QALYs gained by Māori in the base-case and the equity analysis scenario. Under this ‘equity 
analysis’ scenario, the QALYs gained by Māori in all five CVD risk strata increased by approximately 
11%. The largest gain in additional QALYs for Māori, in absolute terms, was observed in risk stratum 
two in which the greatest proportion of the male Māori population in this modelled age-group resides. 
The QALYs gained per capita were greatest in risk stratum five with eight additional QALYs gained in 
the ‘equity analysis’ compared to the QALYs gained by Māori in the base-case. The per capita QALYs 
gained by Māori decreased as CVD risk decreased with risk stratum one gaining one additional QALY 
under the conditions of equal efficacy compared to the QALYs gained by Māori in the base-case. 
Overall, the equity analysis scenario had minimal effect on the overall cost-effectiveness of treatment 
with the FDC AA compared to A+A in each CVD risk stratum. The ethnic groupings combined QALYs 
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gained increased slightly while the total cost-offsets (savings) under the conditions of equity analysis 
were approximately equal to the base-case in all risk strata.  
Table 16: The additional health gain (QALYs) by Māori men aged 60 to 64 years in 2011 who were 
assumed to be on A+A and who were switched to the FDC AA: Base-case vs ‘equity 
analysis’. 
Risk Strata Total Māori QALYs gained Māori QALYs gained per 
1,000 people who took the 
pharmaceuticals  
(46% of Māori in each risk 
strata) 
Five-year absolute CVD risk Base-case Equity analysis Base-case Equity 
analysis 
Risk Stratum 5: >20% 1.37 1.52 72.3 80.2 
Risk Stratum 4: >15%, 20%  3.88 4.31 53.2 59.2 
Risk Stratum 3: >10%, 15% 12.5 14.0 37.7 42.0 
Risk Stratum 2: >5%, 10 25.0 27.9 22.3 24.8 
Risk Stratum 1: 0, 5 4.66 5.17 12.4 13.7 
 Risk Stratum 1: n=19, Risk Stratum 2: n=73, Risk Stratum 3: n=333, Risk Stratum 2: n=1,125, Risk 
Stratum: 1 n=377 
5.3.2 Worse-case adherence and uptake/ethnic group variation in adherence  
The 'worse-case uptake and adherence' scenario which used the value of the lower bound of the 95%UI 
rather the mean for these two parameters, resulted in a modest change from the base-case as both 
the QALYs gained and the cost-offsets (savings) decreased by approximately 22% in each CVD risk 
stratum. Ethnic group variation in adherence had an even smaller influence on the cost-effectiveness 
with the QALYs gained and the cost-offsets (savings) changing by less than 1% (see Table 17). 
5.3.3 Equal efficacy of medicated regimens 
From all the scenario analyses, the base-case was most sensitive to changes in uptake and clinical 
efficacy. Lowering the clinical efficacy for the FDC AA to be equal with A+A in the base-case ('equal 
efficacy' scenario) resulted in a 79% average decrease in the QALYs gained and a 53% average decrease 
in the cost-offsets (savings) in each CVD risk stratum. Although the cost-effectiveness for switching 
remained cost-saving in each risk stratum despite these decreases, the cost-effectiveness was greatly 
decreased (see Table 17).  
5.3.4 80% uptake 
Changing the proportion of the population who were assumed to be on A+A and switched to FDC AA 
from 46% for Māori and 38% for non-Māori in the base-case to 80% at the start of the modelling, had 
the large effect on the cost-effectiveness of FDC AA compared to A+A. This increase in uptake 
approximately doubled the QALYs gained and the cost-offsets, greatly increasing the cost-
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effectiveness. This analysis suggests the potential health gain and cost-savings that could be observed 
if a greater proportion of people were switched from A+A to the FDC AA (see Table 17 ). 
5.3.5 Varying time horizons 
Modelling the future involves uncertainty and the magnitude of this uncertainty increases as the time 
horizon increases. The base-case analysis looked at the QALYs gained and the cost-offsets (savings) 
over a lifetime time horizon. In this scenario analysis, the QALYs gained and the cost-offsets (savings) 
were explored over a five-year, 10-year and 20-year time horizon (albeit with the intervention period 
still set at five years) (Table 18). The number of QALYs gained overall and within each CVD stratum 
increased as the time horizon increased. The additional QALYs gained by switching to the FDC AA at 
five-years, 10-years and 20-years were on average 11%, 34% and 77% of the QALYs gained over a 
lifetime time-horizon (base-case) respectively within each CVD risk stratum. The cost-offset with 
treatment with the FDC AA increased in all CVD risk strata as the time horizon increased from five-
years to 10-years. Cost offsets (savings) increased further from a 10-year to 20-year time horizon for 
risk stratum one and two but decreased for risk strata three to five. The cost-offsets (savings) from 20-
years to the lifetime horizon considered in the base-case decreased. In risk stratum three, four and 
five, the greatest cost-offsets (savings) were observed over a 10-year time horizon, while for risk 
stratum one and two the greatest cost-offsets (savings) were observed over a 20-year time horizon. In 
all risk strata, the cost-offsets (savings) over the lifetime were the lowest of the four time-horizons. 
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Table 17: The additional health gain (QALYs) and the cost-offsets (savings) if New Zealand men aged 60 to 64 years in 2011 who were assumed to be on A+A 
switched to the FDC AA – ethnic groupings combined, scenario analyses. 
Five-year absolute CVD risk 
strata 






Equal efficacy of 
medications 
regimens 
80% uptake of both 
regimens at the 





































Risk Stratum 5: >20% 3.42 -$0.009 3.57 -$0.009 2.67 -$0.007 3.40 -$0.009 0.72 $0.005 6.84 -$0.022 
Risk Stratum 4: >15%, 20% 10.7 -$0.050 11.1 -$0.050 8.35 -$0.038 10.6 -$0.050 2.24 -$0.023 21.3 -$0.118 
Risk Stratum 3: >10%, 15% 44.6 -$0.326 46.0 -$0.326 35.0 -$0.251 44.1 -$0.326 9.23 -$0.142 89.8 -$0.754 
Risk Stratum 2: >5%, 10 197 -$2.51 200 -$2.51 155 -$1.96 195 -$2.51 40.0 -$1.11 408 -$5.71 
Risk Stratum 1: 0, 5 167 -$3.41 167 -$3.41 131 -$2.68 164 -$3.40 33.6 -$1.66 354 -$7.62 
B. QALYs / 1,000 people & $ per person who received either pharmaceutical regimen at the start of the model (uptake)  
Risk Stratum 5 (n=41) 83.0 -$221 86.3 -$221 64.6 -$168 82.1 -$222 17.5 -$115 85.5 -$278 
Risk Stratum 4 (n=178) 60.0 -$281 62.3 -$281 46.8 -$215 59.4 -$281 12.6 -$128 61.2 -$339 
Risk Stratum 3 (n=1,078) 41.4 -$303 42.7 -$303 32.5 -$233 41.0 -$303 8.57 -$132 41.9 -$351 
Risk Stratum 2 (n=8824) 22.3 -$285 22.6 -$285 17.5 -$222 22.0 -$284 4.54 -$126 22.4 -$314 
Risk Stratum 1 (n=14,631) 11.4 -$233 11.4 -$233 8.95 -$183 11.2 -$233 2.30 -$113 11.5 -$249 
*Base-case: 38% of non-Māori and 46% of Māori men aged 60 to 64 assumed to be on A+A switch to FDC AA, five-year intervention period, lifetime time horizon and 3% annual 
discount rate 
**Equity analysis: The morbidity and mortality rates used for non-Māori in the base-case were applied to Māori. All other conditions as per the base-case 
***Worse-case adherence and uptake: Lower value of the 95%UI for adherence and uptake used rather than the median. All other conditions as per the base-case 
Ethnic group variation in adherence: Adherence for both FDC AA and A+A assumed to be 11% lower for Māori than non-Māori. All other conditions as per the base-case 
Equal efficacy of medication regimens: Clinical efficacy for FDC AA assumed to be equal to clinical efficacy of A+A in the base-case. All other conditions as per the base-case 
 80% uptake: initial uptake at the start of the modelling was changed to be 80% for both Māori and non-Māori for the FDC AA and A+A.  
 n=46% of Māori and 38% of non-Māori in each CVD risk stratum  
All values are expected values. All figures are rounded to three meaningful digits.  
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Table 18: The additional health gain (QALYs) and the cost-offsets (savings) if New Zealand men aged 60 to 64 years in 2011 who were assumed to be on A+A 
switched to the FDC AA – ethnic groupings combined, various time horizons 
Five-year absolute CVD risk 
strata 


























A. Overall   
Risk Stratum 5: >20% 0.416 -$0.033 1.41 -$0.035 2.98 -$0.018 3.42 -$0.009 
Risk Stratum 4: >15%, 20% 1.20 -$0.106 4.00 -$0.121 8.88 -$0.082 10.7 -$0.050 
Risk Stratum 3: >10%, 15% 4.65 -$0.474 15.1 -$0.570 34.9 -$0.477 44.6 -$0.326 
Risk Stratum 2: >5%, 10 19.4 -$2.50 59.8 -$3.12 140 -$3.19 197 -$2.51 
Risk Stratum 1: 0, 5 16.5 -$2.80 48.2 -$3.47 111 -$3.88 167 -$3.41 
B. QALYs / 1,000 people & $ per person who received either pharmaceutical regimen at the start of the model (uptake)  
Risk Stratum 5 (n=41) 10.1 -$791 34.0 -$836 72.2 -$433 83.0 -$221 
Risk Stratum 4 (n=178) 6.74 -$597 22.4 -$679 49.8 -$461 60.0 -$281 
Risk Stratum 3 (n=1,078) 4.32 -$440 14.0 -$529 32.4 -$442 41.4 -$303 
Risk Stratum 2 (n=8824) 2.19 -$283 6.78 -$354 15.9 -$361 22.3 -$285 
Risk Stratum 1 (n=14,631) 1.13 -$191 3.30 -$237 7.57 -$265 11.4 -$233 
*Base-case: 38% of non-Māori and 46% of Māori men aged 60 to 64 assumed to be on A+A switch to FDC AA. five-year intervention period, 
lifetime time horizon and 3% annual discount rate 
 Time-horizon over which QALYs and costs accrued was varied from lifetime in the base-case to five-years, 10-years and 20-years. Intervention 
period remained five-years. All other conditions as per the base-case.  
 n=46% of Māori and 38% of non-Māori in each CVD risk stratum  




5.4 Evaluation of the ICER – all sensitivity and scenario analyses, overall and 
by risk strata  
Figure 9 illustrates the impact the all the sensitivity and scenario analyses had on the additional QALYs 
gained and the additional cost-offsets (savings) attributed the use of FDC AA compared to A+A for risk 
stratum three. The patterns illustrated in this figure are indicative of the impact that all the considered 
sensitivity and scenario analysis had in all risk strata and for the risk, strata combined.  
Overall and across all risk strata the scenario analysis ‘worse-case’ and ‘equal efficacy’ reduced the 
cost-effectiveness of the FDC AA compared to A+A by resulting in less QALYs gained and fewer costs 
offset than that observed in the base-case analysis. This effect was more pronounced under the 
conditions of ‘equal efficacy’ than ‘worse-case’ in all five risk strata. Increasing uptake to 80%, on the 
other hand, was the only analysis to increase the cost-effectiveness of the FDC AA compared to A+A 
by increasing the magnitude of both the QALYs gained and the cost-offsets (savings). Using a 0% 
discount rate increased the QALYs gained but reduced the cost-offset (savings) compared to the base-
case in each CVD risk stratum. In risk stratum five using a 0% discount rate, treatment with the FDC AA 
resulted in a cost of $7,000. Varying the model time horizon over which QALYs and cost-offsets 
(savings) could be accrued and using a 6% discount rate resulted in less QALY gain and greater cost-
offsets (savings) compared to the base-case. The ‘equity analysis’, ‘ethnic group variation in adherence’ 
and the two analyses that varied the cost of the FDC, all resulted in only minor changes in the cost-
effectiveness relative to the base-case.  
The ICER of the FDC AA compared to AA was notably influenced by the scenario analysis ‘five-year time 
horizon’, ‘10-year time horizon’, ‘equal efficacy’, ‘0% discount rate’ and ‘80% uptake’. With the 
exception of a 0% discount rate in risk stratum five which resulted in a cost-effectiveness ratio of 
$1,400 per QALY (716 QALYs per million dollars spent), all sensitivity and scenario analysis fell in the 
cost-saving zone of the cost-effectiveness plane. That is, within each risk stratum and all the scenarios 
considered (except for 0% discount rate in risk stratum five) treatment with the FDC AA resulted in 







Figure 9: Cost-effectiveness plane showing the additional QALYs gained and the additional cost-
offsets attributed to the use of the FDC AA compared to A+A among New Zealand men 
aged 60 to 64 assumed to be on A+A in 2011 who then switched to the FDC AA (all 




Chapter 6: Discussion 
6.1 Chapter overview  
This Chapter begins by discussing and interpreting the main results of this thesis and their relationship 
to existing literature. Following this, the strength and limitations of the model method, model inputs 
and intervention parameters are considered. The Chapter then considered the implications and future 
directions from this research and draws conclusions.  
6.2 Main results and interpretation  
6.2.1 Introduction  
This study aimed to determine the health gain, costs and cost-effectiveness of prescribing a two-agent 
FDC for the primary prevention of cardiovascular disease (relative to the same agents taken as 
individual pills) by absolute CVD risk in the New Zealand population. The FDC AA compared to A+A as 
two separate pills were chosen as the basis of this analysis because it was part of an emerging group 
of CVD pharmaceuticals that aimed to address multiple CVD risk factors in a single pill. No 
pharmaceutical formulations that address two or more different CVD risk factors were approved for 
use in New Zealand at the time of this research commencing. Furthermore, the prevalence of New 
Zealand adults who use A+A or more generally a CCB and statin as two separate pills is high.10, 21, 91 It 
was therefore hypothesised that there was a large proportion of the adult population who could 
potentially benefit from switching to the FDC AA and realise the benefits from improved adherence 
and a reduced pill burden. These benefits potentially included improved pharmaceutical efficacy which 
may then lead to a reduction in CVD events and associated hospitalisations. Financial savings may also 
be observed with patients reducing the number of prescriptions they pay for and the health system 
treating less CVD related events.  
An existing MSLT model from the BODE3 Programme was adapted and used to model the incremental 
difference in the QALYs and the costs accrued over a lifetime, if a cohort of New Zealand men aged 60 
to 64 in 2011 who were free from CVD and assumed to be on A+A (46% of Māori and 38% non-Māori) 
were offered to switch to the FDC AA. The model base-case considered a health system perspective, a 
five-year intervention period and lifetime horizon over which the accrued QALYs (health benefit) and 
costs were discounted at 3% annually. Based on the literature, the clinical efficacy of the FDC AA was 
assumed to be greater than A+A reflecting the potential increase in clinical efficacy that occurs as a 
result of improved adherence. Adherence was also considered in the model, with an annual decrease 
in adherence which was greater for A+A than the FDC AA (ie, based on available literature, adherence 
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was assumed to be greater for FDC AA that A+A). For more detailed information on the intervention 
inputs see Table 12.  
6.2.2 Summary of base-case results  
The results of the base-case showed that switching New Zealand men aged 60 to 64 assumed to be on 
A+A to the FDC AA for the primary prevention of CVD improved health while being cost-saving. That 
is, switching to use the FDC AA in this population is likely to result in greater health gains (QALYs) and 
greater cost-offsets (savings) than if the same population remained on A+A, overall and within each 
stratum of CVD risk. Over the lifetime horizon considered in the model, the use of the FDC AA for five-
years resulted in an additional 86.2 QALYs (95%UI 0 to 386) and 1.24 million (95%UI -$6.10 million to -
0.028 million) in cost-offsets (savings) compared to the use of A+A for five-years in the same population 
(albeit not to a significant level for the costs). The ICER overall ranged from cost-saving to $3,570 per 
QALY gained (280 QALYs per million dollars spent). The lowest CVD risk strata had the smallest range 
of cost-effectiveness ranging from cost-saving to $2.12 per QALY (470,000 QALYs per million dollars 
spent). While the remaining four risk strata ranged from cost-saving to $3,000 to $4,000 per QALY (333 
or 250 QALYs per million dollars spent respectively) at the upper bounds of the 95%UI.  
For BODE3 Programme work in New Zealand, a threshold of $45,000 per additional QALY gained 
(approximately the GDP per capita in NZ as recommended by the World Health Organization (WHO)129) 
is used when evaluating and comparing the cost-effectiveness of health sector interventions. Given 
this threshold and an ICER within each CVD risk stratum and overall ranging from cost-saving to $4,000 
per QALY at the upper bounds of the 95%UIs, switching from A+A to the FDC AA appears to be a good 
value for money method to enhance the primary prevention of CVD in New Zealand. Although the 
overall cost-effectiveness of the FDC AA compared to A+A was greater the lower the CVD risk strata, 
considering this threshold suggests that switching to the FDC AA would likely have a positive impact 
regardless of absolute CVD risk at baseline.  
The health benefit and cost-effectiveness of pharmaceuticals in New Zealand for government 
subsidisation are routinely assessed by the Pharmaceutical Management Agency (PHARMAC). The 
economic evaluation results of the pharmaceuticals considered are not made publicly available. 
However, the 2016/17 and 2015/16 PHARMAC Annual Report indicates that the average cost-
effectiveness achieved for funded proposals to the Combined Pharmaceutical Budget (CPB) (includes 
community pharmaceuticals, hospital pharmaceutical cancer treatments and vaccines) was 38 and 52 
QALYs per $NZ million net costs to the health sector in the respective financial years.130, 131 Although, 
the availability of funding and the number of pharmaceutical proposals competing for funding differs 
from year to year, comparing the base-case results of this thesis to the published average of the QALYs 
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achieved by PHARMAC in recent years, demonstrates that the funding of the FDC AA for subsidised 
use in New Zealand would likely be viewed as a good investment. 
Overall, the additional QALYs gained and the additional cost-offsets (savings) attributed to the use of 
the FDC AA compared to A+A were greater the lower the absolute CVD risk. This pattern is largely 
influenced by population numbers, which were greater in the lower risk strata (risk stratum one and 
two) than the higher risk strata (risk stratum four and five). When the results were considered per 
capita (per 1,000 people who received either pharmaceutical regimen at baseline - uptake), the 
additional QALYs gained with the use of the FDC AA instead of A+A, were greatest in the highest CVD 
risk strata (stratum five) and decreased as CVD risk decreased. This suggested, that individuals with 
higher CVD risk and greater capacity to benefit also achieved the highest benefit from switching to the 
FDC AA than remaining on A+A (in relative terms). Information like this provides a rationale for 
prioritising switching the treatment of those who are at greater risk of CVD.  
The additional QALYs gained at the group level by switching from A+A to the FDC AA were greater for 
non-Māori than Māori within in each risk stratum. However, the results per capita exposed to either 
pharmaceutical regimen at the start of the model show, the additional QALY gained by Māori are 
slightly greater than non-Māori in risk stratum one and two. The epidemiology of CVD demonstrates 
that there is an inequity in the proportion of Māori who experience high CVD risk.13 Switching from the 
A+A to the FDC AA, among Māori in CVD risk stratum one and two, appears to be a method which 
could help to address this inequity by having a greater impact on the health of Māori who also have a 
greater burden of health need than non-Māori.  
6.2.3 Scenario and sensitivity analyses  
Clinical efficacy appears to be a large driver of the cost-effectiveness. In the base-case, the clinical 
efficacy of the FDC AA was greater than A+A. To distinguish between the effect of improved clinical 
efficacy and adherence with an FDC, the clinical efficacy of the FDC AA was reduced to be equal to that 
of A+A (as at the very least, FDCs are designed to be equally efficacious as their equivalent 
monotherapies). Under this assumption, the cost-effectiveness of switching from A+A to the FDC AA 
remained cost-saving but was substantially reduced in all five CVD risk strata. Other sensitivity analyses 
that influenced adherence including ‘ethnic group difference in adherence’ and ‘worse-case adherence 
and uptake’ also reduced the cost-effectiveness in all CVD risk strata but by a smaller magnitude than 
that observed in the ‘equal efficacy’ scenario analysis. The results of this model appear more sensitive 
to changes in clinical efficacy than adherence, but further consideration and modelling could be done 
to examine the relationship between adherence and clinical efficacy.  
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The other large driver of the cost-effectiveness ratios was intervention uptake. This scenario analysis 
changed the proportion of the model population who were exposed to either pharmaceutical 
intervention at the start of the modelling to 80% for both Māori and non-Māori and it approximately 
doubled the cost-effectiveness in favour of switching to the FDC. The results of this scenario, highlight 
the substantial health gain and cost-savings that could be seen if a greater proportion of the population 
in this age-group of men were taking a statin and an anti-hypertensive for the primary prevention of 
CVD and were preferentially prescribed the FDC AA instead of A+A.  
The cost of the FDC AA in the model had little impact on the cost-effectiveness. Halving the price of 
the FDC AA increased the cost-offsets (savings) by approximately 11% while doubling the cost 
decreased cost-offsets (savings) by 23%.  
Modelling inherently involves uncertainty and this uncertainty increases the further into the future the 
model runs. At time horizons of five-years, 10-years and 20-years, switching to the FDC AA from A+A 
remained cost-saving within all CVD risk strata. Although the QALYs gained increased over time, the 
cost-offsets (savings) were generally greater under a 10-year and 20-year time horizon. These results 
are likely due to the total health costs of the modelled population increasing the older the cohort gets 
(especially if they live longer as a result of a reduction in CVD events).  
Finally, the discount rate was varied to illustrate the sensitivity of the cost-effectiveness of switching 
from A+A to the FDC AA if the value society places on short-term costs and benefits compared to long-
term costs benefits changes. Except for a 0% discount rate in risk stratum five, the ICER remained cost-
saving despite the change in annual discount rate. In risk stratum five with a 0% discount rate, the ICER 
was $1400 per QALY (716 QALYs per million dollars spent). This is likely a result of the intervention 
allowing people to live for longer, which comes at a future cost that is not discounted away. Although 
no longer cost-saving, this ICER represents a highly cost-effective intervention with a minimal cost per 
QALY when compared to the arbitrary cost-effectiveness threshold of $45,000 per QALY as discussed 
above.  
6.3 Relationship of these results to the existing literature  
This study was the first study internationally to consider the cost-effectiveness of a FDC by differing 
levels of CVD risk (to the author’s knowledge). It was also the first study of a CVD FDC in a New Zealand 
context. A study conducted by Selak et al50 looked at clinical efficacy and adherence to a CVD polypill 
in New Zealand context, but the cost-effectiveness of the intervention has not been assessed. The 
international literature concerning the cost-effectiveness of CVD FDC is limited and is largely 
dominated by evaluations of the polypill. Five other studies were identified that examined the cost-
effectiveness of a two-agent FDC, two of which investigated the cost-effectiveness of the FDC AA. All 
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five identified studies concluded that the use of a FDC was likely to be cost-effective compared to usual 
care, placebo, equivalent monotherapies or one pharmaceutical of the same class. However, 
comparing the results of these studies with the results in this thesis is difficult for multiple reasons. 
Only one study considered the cost-effectiveness in terms of a cost per QALY gained. The other studies 
used alternative cost-effectiveness measures such as a cost per death averted and cost per percentage 
change in LDL cholesterol or SBP which makes the comparison of results difficult. The comparison is 
made more difficult still by the limited internal and external validity of these studies due to the 
evaluation method and model structure used as well as the choice of comparator and selection of 
model inputs. Furthermore, three were sponsored by Pfizer Pharmaceuticals and all involved health 
system costings that were population and country-specific (ie, Korea, Mexico and Australia). This thesis 
builds on the limitations identified in the other identified studies by using a more comprehensive 
model structure that utilised lifetables to inform transition probabilities and reflect the heterogeneous 
nature of CVD incidence, CFR and background mortality by age, sex and ethnicity.  
The available literature on the cost-effectiveness of pharmaceuticals in a New Zealand context is 
limited. Beyond the average cost-effectiveness range of funded pharmaceuticals published in 
PHARMAC’s annual reports (discussed in Section 6.2.2 above), just one published study concerning the 
economic evaluation of pharmaceuticals in a New Zealand context was identified. The study by 
Metcalfe et al in 2003132 listed the ICER of 21 pharmaceuticals funded by PHARMAC between 1998 and 
2002. The figures presented are difficult to interpret and generalise due to the use of a unique unit 
(QALYs gained in the first year of a funded proposal) and a high discount rate (10%).  
The cost-effectiveness of a variety of other health sector interventions have been assessed in the New 
Zealand context. The ICER of primary care interventions assessed by the BODE3 research group that 
used the same modelling methodology and principles as this thesis are more appropriate to compare 
to the results of this thesis. Of note, is that the ICER of switching from A+A to the FDC AA for the 
primary prevention of CVD falls into the same realm as a broad range of interventions in tobacco 
control, dietary salt reduction, falls prevention and cancer treatment and screening which were 
typically found to be cost-saving or cost-effective below the arbitrary threshold of $45,000 per 
QALY.133, 134 It should be noted, however, some of the interventions considered by BODE3 consider the 
entire New Zealand population alive in 2011, while the results of this thesis were restricted to a subset 
population of New Zealand men aged 60 to 64 in 2011. The relationship of the results from this thesis 
to the existing BODE3 literature should ideally be reconsidered when the use of the FDC is considered 
within a broader range of age-groups for the New Zealand adult population.  
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6.4 Potential generalisability of results  
The results of this thesis cover the health gain, health costs and the cost-effectiveness of switching 
from A+A to the FDC AA for the primary prevention of CVD in New Zealand men aged 60 to 64 years 
old (free from CVD, no prior CVD pharmaceutical use). Due to the largely similar clinical efficacy of 
pharmaceuticals within the statin and anti-hypertensive classes,113, 114, 135 the results are probably 
broadly generalisable to the cost-effectiveness of any FDC that contains a statin and an anti-
hypertensive as a primary CVD prevention measure. The results can be used to establish hypotheses 
about the cost-effectiveness of switching to the FDC AA or a statin and anti-hypertensive FDC in 
broader New Zealand population than considered in this thesis. However, future research that 
considers the impact of switching from A+A to the FDC AA in other groups where A+A prescription is 
common would greatly increase the generalisability of the results (ie, a broader age range of New 
Zealand adults and in women). Restricting the model population to this age group of men could have 
underestimated the benefit of switching for Māori, as Māori have a younger age structure than non-
Māori and experience their largest CVD burden at an earlier age.1, 21 
As has been discussed previously in this thesis, adherence and non-adherence is multi-factorial. This 
thesis focused on switching from A+A to the FDC AA for the primary prevention of CVD. Generalising 
the results to secondary prevention is likely to be reasonable, however, it is important to note that the 
multitude of factors that influence non-adherence may be different between a primary prevention and 
secondary prevention context. Adherence to primary prevention medications for CVD is generally 
lower than for secondary prevention medications with studies suggesting that increased motivation to 
manage CVD risk following a CVD event is a contributing factor.5, 27, 136 In the context of this thesis, that 
could mean that the marginal health gain and therefore cost-effectiveness of switching to a FDC could 
be smaller if the FDC AA was used as a secondary prevention measure. Cultural differences between 
countries have also been shown to influences adherence with some studies showing that adherence 
to medications can differ substantially between countries and between different ethnic groups.27, 137, 
138 The difference in factors that influence adherence between various populations should be 
considered before generalising the results of this thesis.  
Using the results of this thesis to generalise or make an inference beyond New Zealand, particularly to 
other high-income countries, is possible but should be done with caution. Caution is advised in part 
because of the highly restricted population group (a narrow age-group, male only) considered in this 
thesis and in part because of difference between the model inputs that may differ between New 
Zealand and other countries. The latter may include health system costs, in particular the 
pharmaceutical cost (ie, it is widely acknowledged that New Zealand typically has considerably lower 
pharmaceutical costs than other high-income countries80, 81), the proportion of the population 
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represented in each CVD risk stratum and the burden of medication non-adherence.27, 137 The 
difference in these inputs could influence the resulting cost-effectiveness. However, given switching 
from A+A to FDC AA regimen appears to be cost-saving, it is reasonable to assume that the same 
intervention would at least be cost-effective in other high-income countries with similar disease 
burden and cost-effectiveness thresholds.  
6.5 Study strength and limitations  
6.5.1 Model methods  
MSLT Markov modelling is a methodology that is increasingly being used in the economic evaluation 
of health interventions. The use of lifetables to better reflect true population heterogeneity in 
transition probabilities (in this case, disease incidence rates and case-fatality rates all by differing levels 
of CVD risk) is a key strength of MSLT Markov modelling that is not captured by a simple Markov model 
or decision tree analysis. Incorporating heterogeneity greatly increases the model's ability to reflect 
the ‘real-world’ and produce more generalisable results. Nevertheless, MSLT Markov modelling has 
limitations. One noteworthy limitation of the MSLT model used in this thesis is that each of the disease 
lifetables (in this case CHD and stroke) were assumed to occur independently of each other. That is, 
although a proportion of the population can reside in both life-table simultaneously, the probability 
(or risk) of having had a stroke is assumed to be independent of an individual’s probability (or risk) of 
having a non-fatal CHD event (a simplifying assumption). Developing a microsimulation model could 
allow an additional degree of complexity to be included, such as allowing the risk of having a CHD event 
to be influenced by the time since the previous CVD event. However, the additional level of data 
required to do this, in addition to the person and computational power to run a microsimulation model 
was outside of the scope of this thesis.  
6.5.2 Model structure 
Baseline model input parameters and uncertainty  
The MSLT model used in this thesis utilised an existing CVD MSLT which was in the process of being 
adapted from the established and validated tobacco MSLT19 (adaption was complete for men aged 60 
to 64 in 2011 only). A key strength of using the established MSLT CVD model was the use of rich 
longitudinal New Zealand specific data on costs and epidemiological parameters that formed the 
model's foundations. Uncertainty around all baseline model inputs and intervention parameters was 
incorporated in the model through ranges assigned to each parameter (95%CIs or SD ranges ( 5% or 
 10% SD – see Table 6)) which were then sampled from in the 2000 Monte Carlo simulations per CVD 
risk stratum, as per established BODE3 methods.  
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Stratification by absolute CVD risk  
A fundamental component and a key strength of the adapted MSLT model was the division of the 
model population into five strata based on five-year absolute CVD risk. To the author’s knowledge, this 
study was the first to consider the cost-effectiveness of a FDC by strata of CVD risk. This adaption 
allowed this research to address the second aim of this thesis and test the hypothesis, that those who 
have higher CVD risk are also the group who would potentially benefit the most from switching from 
A+A to the FDC AA for the primary prevention of CVD. This information is potentially valuable to 
primary care workers who could prioritise FDC uptake to those where the potential health gain and 
cost-effectiveness is highest. Two limitations arise as a result of stratifying the population in this way 
and were a result of the existing model structure. Firstly, the division of the population into CVD risk 
strata was established at baseline and remained unchanged over the five-year intervention period. 
After that five-year period, the CVD risk strata were no longer meaningful and the risk of a CVD event 
for the modelled population after five-years tracked upward as they age. That is, the model did not 
permit movement between CVD risk strata based on the experience of the cohort during the five-year 
intervention period or over the remainder of the model time horizon. Secondly, due to lack of available 
data, intervention parameters such as adherence and uptake could not be different in each risk 
stratum as may be the case in reality. This second point is discussed further in Section 6.5.3.  
The intervention (switching from A+A to the FDC AA)  
The model utilised in this thesis was built to compare an intervention to business as usual (the 
equivalent of doing nothing new). To best compare the cost-effectiveness of switching to the FDC AA 
from A+A, the latter regimen would have been set as the model baseline and the FDC AA would be the 
intervention. Due to the time constraints and the scope of this thesis, adapting the model in this way 
was not feasible. As a result, the model was run in two ways, once with A+A as the intervention (to 
simulate the baseline) and once with the FDC AA as the intervention. The resulting outputs were then 
subtracted to generate the differences between the two regimens. Calculating the cost-effectiveness 
in this way had two caveats which should be noted when interpreting the results. Firstly, the base-case 
analysis involved 2000 Monte Carlo simulations in which a value for each model parameter was 
randomly selected from a range of uncertainty. Therefore, when the results of the iterations from A+A 
and the FDC AA were subtracted, the combination of parameter values that went into generating the 
result of each intervention could have been different. As a consequence of this and the small 
magnitude of health gain associated with either pharmaceutical regimen, approximately 8% of the 
2000 Monte Carlo simulations resulted in negative QALY gains. If the pharmaceutical regimens could 
have been run in the same model, negative QALY gains would not be possible, so these iterations were 
deleted from the overall results. Secondly, the overall ICER does not strictly represent the cost-
effectiveness of the population switching from A+A to the FDC AA. That is, in the model, the same 
 74 
cohort who were modelled to use A+A was not the same cohort who was modelled to use the FDC AA 
due to uptake probabilities in the model. Therefore, the marginal change (in QALYs and costs) if the 
same population switched to FDC was therefore not strictly observed – even though the results are 
likely to provide a reasonable approximation of the uncertainty ranges. Future research could address 
this if more resources were put into the model building to ensure the most appropriate comparator 
was set-up as the model baseline.  
Population  
One limitation of the CVD MSLT is that that the model currently only represents a population of New 
Zealand men aged 60 to 64 who are not currently taking CVD preventive pharmaceuticals and who are 
free from CVD. Although this age group of men was chosen as the first stage of the model adaption for 
several reasons which have been discussed previously, the population modelled is not representative 
of the cost-effectiveness of switching from the AA to the FDC AA in other adult New Zealand age-
groups. Therefore, the cost-effectiveness of switching from A+A to FDC AA should be revisited once 
the CVD MSLT model adaption for the entire adult New Zealand population is more complete (ie, 
including all 50+ age-groups and also women).  
Perspective  
The model adopted a health system perspective. A health system perspective provides valuable 
information for decision makers, in particular, decision-makers who are concerned with health system 
funding who are required to make decisions regarding the distribution of a finite health budget to 
achieve the greatest possible health gain. Benefits and costs from a broader societal perspective would 
consider additional costs such as productivity costs to an individual and the society (eg, from work 
absenteeism due to ill health) were outside of the health system perspective taken in this thesis. It is 
the intention of the BODE3 research group to include productivity costs in future work.  
6.5.3 Intervention parameters 
Pharmaceutical Uptake  
In the base-case, FDC uptake was based on an estimate of the proportion of the model population who 
were taking either a statin, an anti-hypertensive or both (the rationale being that a patient on a statin, 
would also likely benefit from being on an anti-hypertensive and vice versa). Although this estimate is 
based on New Zealand specific data, the proportion of uptake could be higher. For example, recent 
work by BODE3 on modelling triple therapy as a CVD prevention intervention used an uptake rate of 
77% from Wells et al 2017138 which represented the use of CVD pharmaceuticals in NZ adults aged 55-
64 years of age for the secondary prevention of CVD. A sensitivity analysis in this thesis which 
considered an 80% intervention uptake (Māori and non-Māori) suggested that a significantly greater 
gain in QALYs and cost-offsets (savings) could be realised if a greater proportion of the population on 
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an anti-hypertensive and statin switched for the FDC AA. Modelling the effect of targeting FDC uptake 
by those deemed eligible in the CVD risk guidelines, or by CVD risk could be beneficial to consider for 
future research.  
Pharmaceutical uptake was unable to be stratified by CVD risk due to the existing model structure and 
thesis time constraints. Logically, pharmaceutical adherence might be greatest in the higher risk strata 
and lower in the lowest risk strata (eg, if those at the lowest risk levels perceived less need for risk 
reduction and possibly preferred to try just lifestyle changes relative to medication). Following this 
logic, the QALYs gained in the risk stratum four and five are likely to be an underestimation of the real 
world and risk stratum one and two may possibly be an overestimation. Furthermore, it is likely that 
the cost-offset would be greater in risk stratum four and five and lower in risk stratum one and two. 
This is of particular importance to note when considering targeting the use of the FDC to those who 
could benefit most (those with a higher CVD risk).  
Adherence 
The difference in adherence between the FDC AA and A+A was a key intervention parameter. In the 
model, adherence was assumed to decline linearly with each annual model cycle. At the end of the 
five-year intervention period, 63.9% of the population prescribed the FDC AA were classified as 
adherent (> 80% of pill days covered) and 38.4% of the population assumed to be taking A+A where 
classified as adherent. Modelling adherence in this way resulted in some inherent assumptions which 
may differ from what may occur in the real world. These assumptions and the likely impact of these 
assumptions on the results of this thesis are outlined below and should be considered when 
interpreting the results. 
Firstly, the body of existing literature concerning adherence to CVD pharmaceuticals suggests that 
within a population, a decline in adherence is most likely to be observed in the year directly following 
the initiation of a new pharmaceutical and that adherence levels after that remain relatively constant. 
Representing adherence in this way in the model was not possible due to the existing model structure 
and the time constraints of this thesis. The base-case assumption of a linear decline in adherence 
would likely have resulted in an overestimation in the absolute QALYs gained and cost-offsets (savings) 
by both pharmaceutical regimens. This is because a greater proportion of the population was classified 
as ‘adherent’ for a longer period than if the decline in adherence was just in the first year and then 
remained constant. However, this thesis was primarily interested in the difference in the QALYs gained 
and the cost-offsets (savings) between the two regimens. Because the decline in adherence was 
modelled in the same way for both regimens and the difference in adherence was preserved at all 
time-points, the impact on the marginal differences (in health gain, costs and ICERs) from this 
assumption are likely to be minimal.  
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Secondly, adherence and non-adherence are widely acknowledged to be multi-factorial and complex. 
In this model, adherence is assumed to be dichotomous (‘adherent’ with >80 days PDC or ‘not-
adherent’ with less than 80 PDC). In reality, adherence (or non-adherence) occurs on a spectrum. The 
measurement and classification of adherence is greatly contested with a variety of methods used. 
Simplifying adherence in this way was necessary for modelling and is common within adherence 
measurements studies. Nevertheless, this simplification has consequences. The model assumes that 
only the proportion of the cohort who are classified as ‘adherent’ receive the additional clinical benefit 
from taking the pharmaceutical regimen (ie, have the risk of a CVD event lowered), while those who 
were non-adherent do not (ie, do not have their baseline CVD risk lowered). Similarly, those who 
became non-adherent in a later part of a modelled year, receive no additional benefit from previously 
being adherent in that year (and so the benefits are underestimated by the model). As a result of these 
assumptions, it is likely that the total QALY gains and cost-offsets (savings) found in the results are 
underestimates. However, as above, because the ICER in this thesis represents the difference between 
the using FDC AA and A+A and the assumption was the same for both pharmaceutical regimens, the 
influence of this assumption on the ICERs was likely fairly small.  
Thirdly, in the model, adherence is assumed to be the same in all five CVD risk strata. Although the 
association between poor pharmaceutical adherence and increased CVD risk is well established, 
research on if and how adherence varies by CVD risk is lacking. Without evidence to support the 
stratification of adherence between CVD risk, the assumption made appears reasonable. Further 
research in this area would provide valuable information for future modelling involving adherence to 
CVD pharmaceuticals.  
Fourthly, adherence in the model was taken from Patel et al,68 a longitudinal study that looked 
specifically at the adherence of FDC AA relative to its monotherapy components in an American 
population. Although the Patel et al study was thought to be the best one to inform the adherence 
model parameter in this thesis, studies of adherence to CVD pharmaceuticals in a New Zealand 
context139 suggests that the adherence could be higher than that of observed in Patel et al. Future 
research could also explore this issue further. However, it is probably not critical to the relative 
comparison of FDCs to monotherapies.  
Clinical efficacy  
A key strength of this thesis, was an author conducted meta-analyses for identified trials to inform the 
overall clinical efficacy of the FDC AA. The meta-analyses analysed four controlled trials that were 
comparable in study design but were conducted in different populations internationally. The results of 
the meta-analyses demonstrated that there was statistically significant reduction in SBP, DBP and LDL-
C associated with the use of the FDC AA overall and within each study. Although, the 95%CI of the 
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overall measure was relatively small, the high I2 value for each of the meta-analyses suggests that 
heterogeneity between the included studies was high.  
The clinical efficacy of the FDC AA and atorvastatin was informed by a surrogate endpoints (LDL-
cholesterol and blood pressure reduction) which were then translated to RR reductions in stroke and 
CHD by applying standardised relative risk reduction equations. In the absence of long-term data 
regarding the clinical efficacy of the FDC AA and the now well-established link between reductions in 
these surrogate endpoints and long-term CVD event risks, the assumed stroke and CHD relative risk 
reductions for both pharmaceuticals were likely a fair representation of the truth. Uncertainty in the 
clinical efficacy of both pharmaceuticals was in part considered by the 95%CI of each RR and in part by 
the equal efficacy scenario analysis (where the clinical efficacy of the FDC AA was reduced to be equal 
to A+A). Although this scenario showed that the overall cost-effectiveness was highly sensitive to the 
assumed improved clinical efficacy of the FDC over and above the benefit of adherence, it also 
suggested that in the absence of this improved efficacy, improved adherence and a reduction in 
prescription costs alone, are likely to still result in health benefits and net cost-savings.  
The relative risk reduction associated with using either the FDC AA or A+A was assumed to be same in 
all CVD risk strata. However, it is generally considered that those with the highest CVD risk receive 
relatively greater benefit from preventative CVD medications (ie, statins and anti-hypertensives). 
Overall, this potentially results in an underestimation in terms of the absolute QALYs gained and cost-
offset in the higher CVD risk strata and an overestimation in the lower risk strata. As this limitation is 
the same in both pharmaceutical interventions and this study is concerned with the difference in QALYs 
gained and costs-offset, it is unlikely to influence the overall study result. Adverse events were not 
considered in this model, but rather where assumed to be largely represented in the level of adherence 
(ie, people with adverse effects are more likely to become non-adherent).  
Pharmaceutical costs 
The likely cost of the FDC AA in the New Zealand context could not be precisely estimated in the model 
as the FDC AA is not listed on the national pharmaceutical schedule. The price of the A+A regimen was 
known and was used to estimate the price of the FDC in the model. As the study primarily aimed to 
determine the additional health gains, cost and cost-effectiveness, of the FDC in terms of improved 
adherence, efficacy and reduced prescription cost, the cost of FDC was set to be equivalent to the 
monotherapy components. This method is used in other economic analysis83, 85, 87 that model a 
pharmaceutical with an unknown cost and in the absence of international comparisons (primarily due 
to the different funding pharmaceutical funding structures in other countries) this was likely to be a 
reasonable assumption. Two scenario analyses in which the base-case cost of the FDC AA was varied 
to be double or half the base-case (ie, double or half of the equivalent monotherapy) were carried out 
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and had very little influence on the magnitude of cost-offsets. Importantly, the cost of the FDC and 
A+A was based on the 10 mg dose of amlodipine and a 20 mg dose of atorvastatin to best represent 
the cost of the drug that most closely matched the efficacy determined in the efficacy of the FDC AA. 
Although the cost is based on a set dose, the price of the monotherapies at all dosages are still below 
the $0.08 per pill amount used in the maximum cost scenario analysis. As a result, the price of the FDC 
AA relative to the monotherapy combinations is unlikely to influence the magnitude of cost-savings 
and the overall ICER.  
The combined pharmaceutical and pharmaceutical prescription cost of both the FDC AA and A+A were 
applied each annual cycle to those assigned to take the pharmaceutical regimens regardless of 
adherence. This assumption is likely to be representative of the real world where individuals are likely 
to pick up their pharmaceutical scripts, regardless of whether they are adherent (>80% PDC) or non-
adherent. In reality, there could be one 90-day prescription period of the annual four which may not 
be filled, but at a 90-day cost of $8.81 for the FDC AA and $14.02 for A+A, this is unlikely to influence 
the overall cost-effectiveness.  
Intervention period  
Although the model considered the QALYs gained and the cost-offsets (savings) over a lifetime horizon, 
the intervention period in which the population could benefit from either pharmaceutical was only 
five-years. Following the five-year intervention period, the morbidity and mortality rates tracked from 
their values in each strata at the increasing rates seen for the baseline population prior to stratification. 
That is, in addition to pharmaceutical expenditure no longer being accrued, the additional clinical 
benefit of taking the pharmaceutical is assumed to stop. The scenario analysis which looked at cost-
effectiveness over a five-year time horizon and the scenario that extended the intervention period to 
20 years illustrated that despite the intervention period or time horizon, switching regimens is still 
likely to be cost-saving.  
6.6 Conclusions, study implications and possible future directions  
Non-adherence to pharmaceuticals and large pill burdens is an important issue in CVD prevention, 
particularly in populations with a high CVD risk and populations with multiple co-morbidities. Non-
adherence will mean that health gain from treatment effects are not realised and there are potentially 
extra costs to the health system. The use of FDC as a method to reduce pill burdens and consequently 
improve adherence has been used in a range of health conditions. In CVD, two agent anti-
hypertensives have been available since the mid-1950s but the availability of FDCs that target multiple 
(two or more) CVD risk factors have emerged only in the last two decades.7 The impact of FDCs has 
been documented in many studies in the literature which highlight that improved adherence results in 
better risk factor control and reduced CVD events. Given the positive impact of FDCs suggested in the 
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literature, this thesis aimed to investigate if switching from equivalent monotherapies to a FDC was a 
cost-effective method of the primary prevention of CVD. Therefore, the multi-risk factor reducing FDC 
AA was modelled as an example and the results were stratified by absolute CVD risk.  
This thesis was the first study to consider the health benefit, costs and cost-effectiveness of CVD FDC 
by stratified levels of CVD risk internationally and was also the first study of a CVD FDC in New Zealand. 
The results of this work suggest that switching from A+A to the FDC will likely generate additional 
health gain and be a cost-saving to extremely cost-effective intervention for the primary prevention of 
CVD for New Zealand men aged 60 to 64. Although the total QALYs gained and the cost-offsets (savings) 
were greatest in the group at the lowest CVD risk, the per capita results (result per the population who 
received either pharmaceutical regimen at baseline) suggested that populations with higher CVD risk, 
benefited the most from switching.  
The results of this thesis were generated using a validated model with rich input data and robust 
methodological principles. However, the generalisability of results is still somewhat limited due to the 
restricted model population of New Zealand men aged 60 to 64. The results are probably indicative of 
the general cost-effectiveness of FDC containing a statin and an anti-hypertensive in New Zealand 
adults, but they can also generate hypotheses for further research for both younger age-groups and 
also for women. Further New Zealand specific research on the efficacy and adherence of FDCs and 
comparable monotherapies for CVD is likely to strengthen the understanding and potential of FDCs 
and enhance the ability to more accurately model the impacts. Further research considering the use 
of FDCs in secondary prevention would also be of value. 
A large body of international literature exists which demonstrates the positive impact CVD FDC can 
have on medication adherence and clinical efficacy which follows on to health system cost savings. 
This thesis adds to a small field of international evidence on the cost-effectiveness of CVD FDC and 
demonstrates that switching or initiating use of the FDC AA and potentially other CVD FDC compared 
to the equivalent monotherapies is likely to provide additional health gains to New Zealanders who 
are prescribed a FDC compared to equivalent monotherapy and be cost-saving to the New Zealand 
health system. To date, despite the availability of several anti-hypertensive/statin FDCs internationally, 
no multi-risk factor CVD FDC have been listed on the New Zealand pharmaceutical schedule for 
subsidised use by New Zealanders. The results of this thesis should encourage pharmaceutical 
companies who manufacture two-agent multi-risk factor CVD FDC to apply for a pharmaceutical listing 
in New Zealand and motivate health authorities to consider expanding CVD treatment guidelines to 
incorporate the use CVD FDC where appropriate. This research also suggests that greater emphasis 
and recognition of the benefit of FDC in reducing pill burdens and improving adherence is warranted 
by pharmaceutical funding bodies and medical professionals globally and in New Zealand. If such FDCs 
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are not available, then regulatory authorities could solicit the pharmaceutical industry to apply for such 
products to be registered in their jurisdictions.  
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Appendix 1: Summary of studies identified in the structured review of CVD FDCs  
Table 19: Summary of studies identified in the structured review of CVD FDCs (two-agent FDCs and the polypill)  
Study Population Exposure Comparison Effectiveness Costs  Model Information Main results 
FDC anti-hypertensive + a statin 



















• Markov model 
• 2008 baseline. lifetime 
horizon 
• Microsimulation, 224 
patients, characteristics 
determined from a 
national survey  
• Adherence decline in year 
one for FDC 
• Treatment effect 
observed through 
changes in BP and 
cholesterol which 
changes absolute CVD 
risk.  
• 5% annual discount rate 
 
FDC AA compared to current 
treatment - 7,773,063 KRW per QALY 
 
FDC AA compared to current 
treatment - 10,378,230 KRW per life 
year gained  
 
(USD $6000 per QALY, USD $8000 per 
life-year gained) 
(paper reports 1300KRW=$1) 


















• Decision tree model 
• Percentage of patients 
reaching LDL therapy 
goals based on adherence 
to therapy  
• One-year time horizon  
 
Average cost-effectiveness ratio FDC 
AA Korean Won 4123 per 1% 
achievement in LDL goal.  
 
Average cost-effectiveness ratio A+A 
Korean Won 6062 per 1% 






Study Population Exposure Comparison Effectiveness Costs  Model Information Main results 























subset of study 
population 
• Economic evaluation 
piggy-backed on to 
ADVANCE randomised 
control trial  
• No difference in 
adherence 
• Medication taken in 
addition to existing 
medications 
• 4.3 years follow-up 
• 5% annual discount rate 
AU$49,200 per death prevented  
 














• Markov model  
• Lifetime horizon  
• Base-case assumed 
change in adherence 
changed blood pressure  
• Scenario analysis – no 
change in adherence 
FDC was cost-saving to the health 
system compared to equivalent 
monotherapy 



















• Retrospective review of 
outpatient medical 
records informed 
changed in LDL from 
baseline to 8 weeks.  
Cost per 1% reduction in LDL-C levels  
US$2.02 RSV 
US$4.09 E/S 






















• Markov Model  
• Polypill efficacy from the 
Indian Polycap Study 
(TIPs)  
• 3% annual discount rate  
Polypill compared to no intervention: 
ICER $268 per QALY for women with 
10-year CVD risk greater than 15% 
ICER $1041 per QALY for men with a 
10-year CVD risk greater than 15%.  
ICER $449 per QALY men aged greater 
than 55 
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Polypill No treatment  QALY Pharmaceutical 
costs (polypill 
cost 75% of sum 
of 
monotherapies)
+ health system 
resource costs  
• Markov model  
• Microsimulation of 1991 
patients with metabolic 
syndrome. Baseline data 
from an Australian study 
• Polypill efficacy TIPs 
• Discount rate 5% 
Polypill compared to no treatment: 
AUD214,864 per QALY 
 
 





of people from 
Seychelles 













informed by the 
literature) 
• WHO African risk 
equations used to 
calculate baseline CVD 
from survey data  
• Polypill efficacy TIPs 
• Clinical efficacy of 
monotherapies from 
literature  
Number need to treat annually to 
prevent one CVD event 
Targeting BP and Cholesterol - 379 
people  
Polypill CVD risk >10% - 79 people 

















No significant difference in health 
system expenditure. Mean 
pharmaceutical cost-savings per 
patient was $989 ($648 to $1331) per 
patient per year  



















• Markov Model 
• Lifetime horizon  
• 3% annual discount rate  
• Polypill equal to the cost 
of monotherapies  




Mailed Education and disease 
management US$74,000/QALY,  
Polypill US$133,000/QALY 
Only mailed education had an ICER 
<$100,000/ALY 
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Study Population Exposure Comparison Effectiveness Costs  Model Information Main results 
Megiddo 












• Model structure unclear  
• No difference in 
adherence  
• Polypill cost assumed to 
be less than equivalent 
monotherapy  
 
Polypill $1690 per DALY averted 
Monotherapy components - $6450 
per DALY averted 















system costs  
• Markov Model 
• 10 year time horizon  
• 3.5% annual discount rate 
• Adherence rate UMPIRE 
trial, greater adherence 
for polypill  
• Assumed similar efficacy 
between monotherapies 
and polypill (ie, 
adherence is primary 
difference) 
ICER GBP8200 per QALY 
(81.5% chance polypill is CE at 
GBP20,000 per QALY threshold) 






















and patient  
• Markov model  
• Clinical efficacy of polypill 
multiplicative effect of 
monotherapies  
• Lifetime horizon 
• Polypill cost based on 
expert opinion  
Polypill was most cost-effective 
option. 
$500 per annually for the Polypill the 
intervention resulted in A$13,000 per 
DALY when provided at mainstream 
GP clinic and A$21,000 per DALY from 











Study Population Exposure Comparison Effectiveness Costs  Model Information Main results 
Three agent polypill (statin + three anti-hypertensive) 
Ferket et 
al 201790  
Primary 
prevention of 










QALY  Pharmaceutical 
and health 
system costs 
• Microsimulation of 
260,000 
• Lifetime horizon  
• Modelled risk of CVD, 
diabetes and non-CVD 
death  
• 3.5% annual discount rate  
• Disutility of daily 
medication considered 
Prescribing monotherapies to >20% 
CVD risk group was the most cost-
effective strategy. Polypill strategies 
had greater QALY gains but were 
more costly.  
/ = FDC, + = monotherapy combination, T2DM = type two diabetes mellitus, KRW= Korean Won, QALY = Quality-adjusted life-year, ACER= average cost effectiveness ratio, BP = 
blood pressure 
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Appendix 2: Basic Description of the BODE3 Cardiovascular Disease 
Multi-State Life-Table Model 
Nhung Nghiem1, Nick Wilson1  
1 BODE3 Programme, University of Otago, Wellington, New Zealand 
Background to the multi-state life-table model 
We adapted the BODE3 Tobacco Control multi-state life-table (MSLT) model from which we have 
published results from previously.1 2 3 4 This model benefits from rich national epidemiological data by 
sex, age, and ethnicity (Māori and non-Māori), as well as costing data. Results from the CVD 
component of this model have also been validated via a head-to-head comparison with a separate 
model with a different structure and using different software (a CVD model built in TreeAge and used 
for dietary salt interventions5 6 7). 
The data in this MSLT Model are used to estimate QALYs gained and net health system costs over the 
remaining life of the 2011 New Zealand population (n = 4.4 million). The specific adaptations made are 
outlined in more detail below. 
Integrating CVD risk data from a synthetic national population  
As the BODE3 Tobacco Control MSLT Model lacked data on grouping individuals by level of absolute 
CVD risk, we considered work at Auckland University that used New Zealand-specific CVD risk 
prediction equations.8 The variables required for the risk equation predictions were: age, sex, ethnicity, 
social deprivation, smoking status, diabetes status, personal history of CVD, blood pressure and lipid-
lowering medication treatment, systolic blood pressure (SBP), the total cholesterol to high density 
lipoprotein cholesterol ratio (TC: HDL), and family history of premature CVD (with these obtained from 
the PREDICT dataset, Auckland University). These risk equations were then applied to a synthetic 
population of 2,451,229 New Zealand adults to estimate numbers and rates of CVD events. This 
population was formed by extracting all (anonymised) 30-84-year-old respondents to the 2013 census, 
with variables on age, sex, ethnicity, social deprivation and smoking. Uncertainty was generated by 
sampling from 100 synthetic populations. Full details of this synthetic data generation are provided 
elsewhere.8  
We first compared the results using the data from the synthetic population with the BODE3 Tobacco 
Control MSLT Model in its unmodified state. For the particular comparison we aimed to achieve, we 
focused on the population aged 60-64 years who were not on CVD preventive medication (with 
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standard deviations of the sampled means) and who had no previous diagnoses of CVD in the BODE3 
MSLT Model and no previous diagnoses of the following: CVD, chronic kidney disease, rheumatic heart 
disease, congestive heart failure and atrial fibrillation.8 Table 1 provides an example of the data for 
non-Māori men aged 60-64 years. We selected this age-group as just an initial starting point, though 
this age-group is of some particular interest as it is the working age with the highest rate of CVD and 
improving health in this age-group may enhance productivity (for those citizens who continue in the 
paid workforce after age 65 years). 
Table 1: Example data for the predicted five-year risk of a CVD event for the synthetic national 
population for non-Māori men (60-64y, with no past CVD events and on no CVD 
medication, Knight et al8) 
Five-year cumulative risk (%) 
category for CVD events (fatal 
and non-fatal)* 
Population (non-Māori men) Average risk within each risk 
strata 
 N SD % SD 
Risk: >20 56 7 22.9 0.35 
Risk: >15, ≤20 265 16 16.8 0.08 
Risk: >10, ≤15 1882 42 11.7 0.03 
Risk: >5, ≤10 19,577 140 6.5 0.01 
Risk: >0, ≤5 36,319 147 3.6 0.005 
Total 58,099    
Average risk**   5.0  
* New Zealand guidelines9 suggest the following thresholds for commencing consideration of  CVD preventive 
pharmacotherapy: statins at ≥10% risk, anti-hypertensives at ≥10% risk, and antiplatelet therapy at ≥20% risk. But for various 
reasons these may be out-dated thresholds.10 
** Calculated using the average risk within each stratum of risk. 
Building CVD risk stratification to create the BODE3 CVD MSLT Model and re-calibrating it 
We then took the BODE3 Tobacco Control MSLT Model and modified it to create the BODE3 CVD MSLT 
Model. This involved splitting it into three separate components (with replication for each 
sex/ethnicity grouping in the age 60-64-year-group). 
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Population A: This was the group who were not on any CVD medications and did not have prevalent 
CVD in 2011. This group was then divided into five strata of differing levels of five-year absolute risk of 
a CVD event as per the proportions in the synthetic population work by Knight et al8 but with the 
original MSLT Model population numbers. It is this population that was the intervention population in 
the model ie, potentially offered CVD preventive pharmacotherapy. 
Population B: This was the group with no prevalent CVD in 2011 but who were already on CVD 
medication. This group were given incidence rates of CVD based on the estimated five-year absolute 
risk of a CVD event as per the synthetic population work by Knight et al8 (but with the original BODE3 
MSLT Model population numbers).  
Population C: This was the group who had prevalent CVD in 2011, regardless of medication status) 
Again, the proportion in this group was derived from the synthetic population distribution, but with 
the original BODE3 MSLT Model population numbers.  
Collectively these three groups cover all New Zealand citizens (for each age/sex grouping). In addition, 
we needed to provide unique case fatality rates (CFRs) for the strata in Group A. There were no New 
Zealand data for this (the case fatality data exist by age-group only11) so we considered the results 
from the meta-analysis by Zambon et al 201412 and used the regression equation for CVD mortality by 
CVD incidence (Figure 2(c) in Zambon et al).  
There is also evidence that those with elevated CVD incidence also have relatively elevated non-CVD 
mortality rates (eg, data abstracted from the meta-analysis by Thomopoulos et al 201413 albeit without 
age-standardisation). Based on this evidence from Thomopoulos et al, we assumed that there was a 
doubling in non-CVD mortality rates across the five strata of CVD risk in Population A, albeit with wide 
uncertainty. 
To maximise overall model coherence, and comparability with other BODE3 cost-utility analyses, we 
then performed the additional scaling steps so as to achieve 100% matching of the cumulative count 
of incident cases of CVD after five years, and then 100% matching of the number of CVD deaths after 
five years in the revised model with the original BODE3 Tobacco Control MSLT Model. This involved 
minor scaling of the CVD incidence rates, the case fatality rates and the background mortality rate. 
Addendum 
Since the analysis by Tal Sharrock for this thesis in 2017, we have performed in 2018 automated 
optimisation processes and also more sophisticated long-term model calibration of this CVD MSLT 
Model. As a result there are likely to be minor differences between the work in this thesis and future 
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Appendix 3: Summary of publications identified in the structural review for the clinical efficacy of the FDC AA  
Table 20: Summary of publications identified in the structural review for the clinical efficacy of the FDC AA 
Trial  Study Design/Study 
Population  
Intention to treat 
population 
(competed study) 
Exposure Comparison Duration 
(weeks) 
Change in Low Density Lipoprotein (LDL) and Systolic Blood 
Pressure (SBP)  
Flack et al 
2008 101 
Open Label, non-






FDC AA * 
 
No comparison 20 Mean percentage change from baseline LDL: –23.6% (95%CI-26 
to -21.2) 
Mean change from baseline SBP: –17.5±14.8 mmHg 
 





(Australia, Asia, Latin 
America, Africa/Middle East)  
1638 
(99%) 
FDC AA * 
 
No comparison 14 Mean percentage change from baseline LDL: -28.6%(95%CI: -30.2 
to -27.0) 
Mean change from baseline SBP: -20.2 (95%CI: -20.9 to -19.6) 
Hobbs et al 
2009103 
Open Label, non-
comparative trial (JEWEL I) 
UK and Canada  
2245 
(99%) 
FDC AA * 
 
No comparison 16 Mean change from baseline LDL: -0.90 mmol/L 
Mean change from baseline SBP: -20.4 mmHg 
Open Label, non-
comparative trial (JEWEL I) 
Europe 
Mean change from baseline LDL: -1.09 mmol/L 
Mean change from baseline SBP: -21.8 mmHg 
Blank et al 
2005 
Open Label, non-




FDC AA * 
 
No comparison 14 Mean percentage change from baseline LDL: -32.7% (SD:17.9) 
Mean change from baseline SBP: -17.1 (SD:12.7) 
Neutel et al 
2009104 
Randomised, double-blind, 
placebo controlled trial 




FDC AA (5 mg/ 
20mg) 
Placebo 8 Difference in least square mean LDL: -45.6 (95%CI: -52.5 to -38.4) 
Difference in least square mean SBP: -7.9 (95%CI: -12.7 to -3.0) 
Fedacko et 
al 2013105 
Open label, observational 
study (The STRONG DUET 
study) Slovakia  
1406 
(99%) 
FDC AA + existing 
treatment 
(5/10, 10/10 mg) 
No comparison 
 
12 Mean LDL baseline/12 weeks: -3.89 (SD:0.80)/2.84 (SD:0.66) 
Mean SBP baseline/12 weeks: -159.99 (SD:14.10) /132.01 
(SD:9.36) 
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Trial  Study Design/Study 
Population  
Intention to treat 
population 
(competed study) 
Exposure Comparison Duration 
(weeks) 
Change in Low Density Lipoprotein (LDL) and Systolic Blood 
Pressure (SBP)  
Hradec et al 
2013106  
Post-hoc analysis of CRUCIAL 
Primary Prevention  
1231 
(90%) 
FDC AA (5/10. 
10/10 mg) 
Usual Care 52 Percentage difference in least square mean LDL: -26.8 (95%CI: -
30.7 to -22.9) 
Difference in least square mean SBP:-5.9mmHg (95%CI: -8.2 to -
3.5) 
Zeng et al 
2016107 





FDC AA ( 5/20 
mg) at 10pm daily 
A+A (5+20 mg) 
7am daily 
8 Absolute difference from baseline LDL: exposure -1.24 (±0.69) 
comparison: -1.16 (±0.76) 
Absolute difference from baseline SBP: Exposure: -14.1 (±4.5) 





prospective, open labelled 
parallel design cluster 
randomised control trial. 
(CRUCIAL) - Asia, Middle 
East, Europe and Latin 
America 
1324 
(88.1% FDC AA, 
94% usual care) 
FDC AA (5/10 to 
10/10 mg)**. 
Usual care 52 Percentage difference in least square mean LDL: -27.1 (-30.9 to -
23.4) 
Difference in least square mean SBP: -5.8 mmHg (-8.0 to -3.5) 
Grimm et al 
2010109 
Randomised, double-
blinded, double dummy, 




amlodipine (5 to 
10 mg) 
FDC AA 5 to 10 
mg/20 mg) 
6 Percentage difference in least square mean LDL: -41.1 (95%C: I-
45.8 to -36.3) 





Post hoc analysis of the 
CAPABLE trial (open-label 
non-comparative, 








20 Only looked at percentage goal attainment 
*Doses: 5/10, 10/10, 5/20, 10/20, 5/40, 10/40, 5/80, 10/80 mg ** Up titration to 10/20 mg and 10/20 mg was approved in specific country : Sponsored by a Pharmaceutical company.  
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Appendix 4: Summary of publications identified in the structural review for the clinical efficacy of amlodipine  
Table 21: Summary of publications identified in the structural review for the clinical efficacy of amlodipine  










CHD  Stroke 
Briasoulis et al 
2014115 
Effect of anti-hypertensive on 
CVD outcomes among those 
aged 65+ years included in the 
review, 1970 to 2012 - 
prospective RCT only  
Meta-analysis observed 
intention to treat  
Anti-
hypertensive 
with a decrease 



























 / OR 0.63 





Law et al 2009114 RCT trials that looked at the 
effect of anti-hypertensive and 
recorded CHD events and 
strokes.  
108 studies compared with 




general and by 
class 












Thomopoulos et al 
2015113 
RCT trials from 1966 to 2013 
Included intentional and non-
intentional blood pressure RCT  
the included studies had to 
have a minimum 40% of the 
study population as anti-
hypertensive and all were 












































CHD  Stroke 
Thomopoulos et al 
2014116 
RCT trials from 1966 to 2013 
Included intentional and non-
intentional blood pressure RCT  
the included studies had to 
have a minimum 40% of the 
study population as anti-
hypertensive and all were 
primary care focused  
anti-
hypertensive 






































Sundstrom et al 
2014 117 
Trials had to have a minimum of 
1,000 patients years of planned 
follow up to be included and 
the main results had not been 
published before the study 
protocol was complete 
BP lowering 
drugs 







See study publication Risk ratio and Risk difference for Stroke, CHD, 
HF, CVD death and all-cause death per 5-year risk of the event. 
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Appendix 5: Summary of publications identified in the structural review FDC AA adherence  
Table 22: Summary of publications identified in the structural review FDC AA adherence 
Study  Study Type  Population  Number of 
Participants 
Exposure  Comparison Duration Adherence Outcome  
Zeng et al 
2016107 
Case-control study  Primary CVD prevention, China 200 FDC AA at 10 
pm daily 
(5 mg/ 20 
mg)  





Number of pills missing from the prescription 
bottle.  
Compliance was greater among FDC AA than A+A 
 
Simons et al 
201169 
Retrospective 
cohort study using 
Pharmaceutical 
Benefits Scheme 
data from Australia  
Analysis of a random 10% 
sample of Pharmaceutical 
Benefits Scheme data, Australia  
10350 FDC AA A+A   Adherence: median persistence time (MPT) over 
six months 
MPT FDC AA: 35 months (95%CI: 33 to ≥38 
months) 
MPT A+A: 7 months (95%CI: 6-8months)  
Hazard Ratio of cessation of FDC AA vs FDC AA: 




cohort study using 
administrative 
claims data in the 
US 
Patients previously taking a CCB 
or statin who began FDC AA or 
added a CCB or statin resulting 
in monotherapy combination 
19,447 FDC AA CCB + Statin Six months 
adherence 
 
Adherence: Proportion of days covered (≥ 80% = 
adherent) 6. months 
Adjusted odd ratio FDC AA vs CCB+statin: 
 4.7 (95%CI: :4.22 to 5.23) 
Hussein et al 
2010122 
Retrospective study 
using claims data 
from lifelink: health 
plan claims US 
Patients continuously enrolled 
in a managed care over study 
period with a pharmacy -45.6 (-
52.5 to -38.4) claim for FDC AA 












6 months  Adherence: Proportion of days covered (≥ 80% = 
adherent) 6 months 
Adjusted OR (95%CI: ) for adherence FDC AA vs 
A+A 
No CCB or Statin: 1.06 (0.87 to 1.30) 
CCB, no statin: 2.31 (1.71 to 3.13) 
Statin, no CCB: 1.80 (1.40 to 2.31) 
CCB+statin: 1.12 (0.98 to 1.27) 
 103 
Study  Study Type  Population  Number of 
Participants 





among US enrolees  
Patients with hypertension who 
filled a new prescription for FDC 
AA or a statin. Prior use of 
statin, FDC AA or amlodipine in 





add a statin  
180 days  Adherence: Proportion of days covered (≥ 80% = 
adherent), 180 days 
Adjusted odds ratio of adherence attainment 
(>80 PDC) at 180 days follow up  
FDC AA vs stain add-on odds ratio 1.64 
(95%CI:1.42 to 1.89) 
Persistence greater for FDC AA than A+A 
Patel et al 
2008 68 
Retrospective 





Patients continually enrolled in 
healthcare insurance over study 
period, newly started on CCB or 
statin  







180 days Adherence: Proportion of days covered (PDC) 
(≥80% = adherent)  
Mean PDC % (180 days): FDC AA 81%, A+A 72%,  
 
Adjusted odd ratio of achieving PDC ≥80% over 
180 days FDC AA vs A+A: 1.95 (95%CI:1.80 to 
2.13) 
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